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1. SUMMARY 
 
The advent of combinatorial antiretroviral therapy proved to be highly effective in 
controlling HIV-1 disease progression, transforming AIDS from a deadly to a 
chronic condition. However, major current issues are systemic drug toxicity, 
generation of drug resistant viral mutants and persistence of a latent viral 
reservoir. In addition, drug-based regimens require daily intake and many patients 
cannot maintain the high level of adherence necessary for viral control. Given the 
limitations of the current therapeutic approaches and the absence of any effective 
vaccination strategy against HIV-1 infection, there is a pressing need to develop a 
curative treatment. The first reported cure of HIV-1 infection was provided by the 
apparent eradication of the virus in a patient transplanted with hematopoietic stem 
cells (HSCs) from a donor lacking the functional CCR5 co-receptor, which is used 
by most HIV-1 strains to enter target cells. However, while an important proof-of-
principle, few individuals could benefit from such procedure due to toxicities of 
allogeneic rejection and limitations of finding compatible CCR5-negative donors. 
Therefore, gene therapy approaches aimed to modify autologous HSCs in order to 
render them resistant to HIV-1 infection have emerged as a promising direction. If 
successfully engrafted, these cells would offer continuous, long-term production 
of virus-resistant immune cells. To this end, several anti-HIV-1 genes have been 
developed and tested both in preclinical and clinical settings and, among these, 
RNA interference (RNAi)-based approaches represent one of the most powerful 
tools. 
Starting from these considerations, this study was aimed to develop lentiviral 
vectors expressing anti-HIV-1 RNAi triggers and to test their efficacy in relevant 
human primary cells for HIV-1 infection, including CD4+ T lymphocytes and 
macrophages. The final goal of the research project is to use the most effective 
and safe vector(s) to genetically modify HSCs harvested from AIDS-related 
lymphoma (ARL) patients, that offer a unique opportunity to evaluate anti-HIV-1 
gene therapy strategies in an ethically acceptable clinical setting, as they often 
undergo HSC transplantation.  
To account for HIV-1 variability, we selected multiple RNAi triggers, including a 
short hairpin RNA (shRNA), generating one single small interfering RNA 
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(siRNA) against either the CCR5 cellular gene (shCCR5) or the vif viral gene 
(shvif), and a long hairpin RNA, giving rise to two different siRNAs against the 
viral tat and rev overlapping first exons (lhtat/rev). Overall these molecules inhibit 
different steps of the HIV-1 life cycle, including entry into target cells (shCCR5), 
gene expression (lhtat/rev) and infectivity of the newly produced particles (shvif). 
In the first part of the work, we constructed vectors expressing the shCCR5, the 
shvif or the lhtat/rev as a single transcriptional unit under the control of different 
human polymerase III promoters (i.e. U6, 7SK or H1). These vectors allowed us 
to investigate promoter influence on the siRNA silencing activity, finding out the 
best combination of promoter-RNAi trigger for the development of a 
combinatorial antiviral approach. As a next step, we obtained combinatorial 
vectors simultaneously expressing the above described siRNAs, as independent 
transcriptional units within the same vector backbone. To optimize vector design, 
a number of different vectors were developed by using either the same or distinct 
promoters driving the expression of each RNAi trigger. Moreover, the 
transcriptional units were cloned in different position with respect to each other 
within the vector framework. Considering that the use of multiple highly active 
RNA polymerase III promoters can potentially saturate the endogenous 
microRNA biogenesis pathway, we also explored an alternative combinatorial 
strategy, based on the use of an extended shRNA (e-shRNA). This molecule 
simultaneously expresses the three siRNAs targeting the CCR5, the vif and the 
tat/rev transcripts, under the control of the U6, the 7SK or the H1 promoter. When 
comparing the antiviral activity of all the different combinatorial platforms, we 
could identify two vectors (i.e. U6shCCR5-7SKshvif-H1lhtat/rev and H1e-
shRNA) conferring highly potent protection against HIV-1 infection in both cell 
lines and human primary cells, in the absence of cytotoxicity.  
Overall, our findings highlighted some important strengths and pitfalls of different 
approaches used for multiple siRNAs delivery, providing valuable insights for the 
design and application of reliable combinatorial RNAi to counteract HIV-1 
replication. In addition, this study contributed to the identification of new anti-
HIV-1 combinatorial platforms that, once shown to be effective and safe in vivo, 
may be next in line for clinical testing. 
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2. SOMMARIO 
 
Nonostante l’impiego di associazioni di farmaci nel corso dell’infezione da HIV-1 
determini una riduzione della carica virale e ritardi la progressione della sindrome 
da immunodeficienza acquisita (AIDS), la tossicità dei farmaci, la comparsa di 
virus resistenti e la persistenza del virus in specifici compartimenti anatomici e 
cellulari rappresentano una sfida per il controllo a lungo termine dell’infezione. In 
tale contesto si inserisce il crescente interesse della comunità scientifica allo 
sviluppo di strategie terapeutiche innovative. Il primo importante successo nella 
cura dell’infezione da HIV-1 è stato ottenuto in seguito al trapianto allogenico, in 
un paziente leucemico HIV positivo, di cellule staminali ematopoietiche (HSCs) 
naturalmente resistenti all’infezione a causa di una mutazione a livello del 
corecettore virale CCR5. Tuttavia, il potenziale rischio di rigetto e la difficoltà di 
reperire donatori compatibili, non consentono l’adozione diffusa di questo 
approccio. Il risultato ottenuto supporta, invece, l’idea che la modificazione 
genetica delle HSC, che rappresentano i precursori di tutte le cellule coinvolte 
nella patogenesi dell’infezione da parte di HIV-1, possa generare un sistema 
immunitario permanentemente resistente al virus. Negli ultimi anni sono stati 
sviluppati diversi approcci di terapia genica finalizzati all’espressione di geni anti-
HIV-1 nelle HSC. Tra questi, gli approcci basati sulla tecnica dell’RNA 
interference (RNAi) rappresentano un potente strumento in grado di inibire la 
replicazione virale. 
Partendo da questi presupposti, lo scopo del presente studio consiste nello 
sviluppo di vettori lentivirali esprimenti small interfering RNA (siRNA) in grado 
di inibire la replicazione di HIV-1 e di testarne l’efficacia in cellule primarie 
umane fisiologicamente rilevanti per l’infezione virale, tra cui macrofagi e 
linfociti T CD4+. L’obiettivo ultimo del più ampio progetto di ricerca, in cui si 
inserisce questo lavoro, è l’impiego dei vettori antivirali più efficaci per la 
manipolazione genetica di HSC derivanti da pazienti HIV positivi affetti da 
linfoma. Questi pazienti rappresentano, infatti, un’opportunità unica per valutare 
una terapia anti-HIV-1 basata sull’impiego di HSC ingegnerizzate in un contesto 
clinico eticamente accettabile, poichè sono spesso sottoposti a trapianto di HSC. 
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A causa dell’elevato tasso di mutazione associato alla replicazione di HIV-1, sono 
necessarie strategie terapeutiche combinatorie al fine di ridurre il rischio di 
insorgenza di resistenze. Pertanto, sono state selezionate le seguenti molecole in 
grado di inibire diverse fasi del ciclo biologico virale: due short hairpin RNA, 
codificanti un singolo siRNA diretto contro il trascritto del gene cellulare CCR5 
(shCCR5) o del gene virale vif (shvif) e una long hairpin RNA, codificante due 
siRNA diretti contro il trascritto comune del primo esone dei geni virali tat e rev 
(lhtat/rev).  
Nella prima parte del lavoro, sono stati ottenuti vettori codificanti le singole unità 
trascrizionali esprimenti shCCR5, shvif e lhtat/rev sotto il controllo di diversi 
promotori umani della polimerasi III, tra i quali U6, 7SK e H1. È stata, quindi, 
valutata l’attività di silenziamento genico dei singoli siRNA, allo scopo di 
identificare la migliore combinazione di promotore-siRNA per il successivo 
sviluppo di approcci antivirali combinatori. In seguito, gli siRNA sopradescritti 
sono stati clonati tutti all’interno di uno stesso vettore sottoforma di unità 
trascrizionali indipendenti. In particolare, al fine di ottimizzare il design dei 
vettori, sono state ottenute multiple piattaforme combinatorie, che differiscono 
l’una dall’altra per i promotori che guidano l’espressione degli siRNA e per la 
posizione delle unità trascrizionali. Poiché la presenza di promotori multipli 
potrebbe causare la saturazione del pathway cellulare di biogenesi dei microRNA, 
è stata sviluppata una strategia combinatoria alternativa, basata sull’impiego di 
extended shRNA (e-shRNA). Questa molecola è in grado di esprimere sotto il 
controllo di un singolo promotore i tre siRNA contro i trascritti dei geni CCR5, vif 
e tat/rev. Lo studio dell’attività antivirale delle diverse piattaforme combinatorie 
ha portato all’identificazione di due vettori (U6shCCR5-7SKshvif-H1lhtat/rev e 
H1e-shRNA) in grado di inibire efficientemente la replicazione di HIV-1 sia in 
linee cellulari, che in cellule primarie umane, in assenza di citotossicità. 
Nel complesso, i risultati ottenuti evidenziano aspetti importanti che devono 
essere presi in considerazione per lo sviluppo di approcci combinatori basati su 
RNAi finalizzati all’inibizione della replicazione di HIV-1. Il presente studio ha 
portato, inoltre, all’identificazione di nuove piattaforme combinatorie anti-HIV-1 
che potrebbero essere testate in futuri studi clinici, una volta accertata la loro 
efficacia e sicurezza in vivo nel modello animale. 
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3. ABSTRACT 
 
Acquired immunodeficiency syndrome (AIDS) remains one of the most important 
global public health concern. Although antiretroviral therapy has improved 
survival in HIV-1-infected patients, drugs cannot eradicate the virus and are 
associated with toxicity and resistance. Gene therapy holds considerable promise 
as an alternative or complementary strategy for the treatment of HIV-1 infection 
and, in this context, RNA interference (RNAi)-based strategies represent one of 
the most powerful approaches. Stable expression of short hairpin RNAs (shRNAs) 
targeting viral genes or cellular co-factors in virus target cells can render them 
resistant to infection. In this study, lentiviral vectors expressing shRNAs targeting 
the viral genes vif, tat/rev and the cellular gene CCR5 were developed. To account 
for HIV-1 variability, we adopted combinatorial RNAi approaches based on the 
simultaneous expression of the different shRNAs either from distinct promoters or 
as an extended shRNA. The biological activity and safety of the developed 
vectors were investigated both in cell lines and in human primary cells. Our 
results showed that vector efficacy is influenced by several constraints, depending 
on the adopted combinatorial platform. Among these, promoter selection, relative 
position of the shRNA cassette within the vector framework and presence of 
repeated sequences turned out to be key factors to be considered. Importantly, we 
identified new effective anti-HIV-1 RNAi-based platforms that provided robust 
protection against viral infection. Overall, these data confirmed that combinatorial 
RNAi is a feasible approach to counteract HIV-1 replication, highlighting some 
important strengths and pitfalls of different strategies used for the delivery of 
multiple RNAi effectors. These findings might contribute to the development of a 
reliable HIV gene therapy approach for future clinical applications. 
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4. INTRODUCTION 
 
4.1 The human immunodeficiency virus type I 
 
Acquired immunodeficiency syndrome (AIDS) caused by human 
immunodeficiency virus type1 (HIV-1) infection remains one of the most 
important global public health threats (Ringpis et al., 2012). Worldwide, more 
than 35 million individuals are infected with HIV-1 and each year approximately 
2 million people are newly infected with no effective vaccine available in both 
developed and underdeveloped countries (Global Report UNAIDS, 2013). 
HIV-1 is a lentivirus, member of the viral family Retroviridae, that was first 
discovered in 1983 (Barré-Sinoussi et al., 1983). Retroviruses are characterized 
by their use of viral reverse transcriptase and integrase enzymes for stable 
insertion of viral genomic information into the host genome (Terwilliger et al., 
1990). The lentivirus appellative refers to the long period of time elapsing 
between the initial infection and the onset of the disease, that can protract over a 
period of months or even years. 
The HIV-1 genome consists of two linear positive-sense single-stranded RNA 
molecules of approximately 9 kb in length that encode nine proteins (Figure 
4.1A). The three largest open reading frames encode the major structural and 
enzymatic proteins: Gag, Pol and Env. The gag gene encodes viral core proteins, 
the pol gene encodes a set of enzymes required for viral replication and the env 
gene encodes the viral surface glycoproteins. In addition to these major proteins, 
the HIV-1 genome encodes the regulatory proteins Tat and Rev, which activate 
viral transcription and control the nuclear export of viral transcripts, respectively, 
and the accessory proteins Vif, Vpr, Vpu and Nef, that are essential for viral 
infectivity and spreading during in vivo infection (Feng and Holland, 1988; Malim 
et al., 1989). Besides the protein-encoding regions, cis-acting elements are 
interspersed throughout the HIV-1 genome. Genes are flanked by regulatory 
sequences, consisting of repeat elements (R) followed by 5’ unique elements (U5) 
at the 5’ terminus of the RNA genome, and of 3’ unique elements (U3) followed 
by repeat elements (R) at the 3’ terminus of the RNA genome. During the reverse 
transcription process, these sequences undergo duplication giving rise to identical 
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5’ and 3’ long terminal repeats (LTR) consisting of U3-R-U5 sequences at the 
DNA genome termini. The two LTRs contain signals important for provirus 
integration into the host genome (att repeats), enhancer/promoter sequences, the 
Tat protein binding site (transactivation response element, TAR) and the 
polyadenylation signal (polyA). Other cis-acting sequences within the HIV-1 
genome include the primer binding site (PBS), to which tRNALys binds to initiate 
reverse transcription, the viral RNA packaging/dimerization signals (Ψ and DIS), 
the central polypurine tract (cPPT) and the central termination sequence (CTS), 
that lead to the formation of a three-stranded DNA structure called the central 
DNA Flap during reverse transcription. In addition, there are the Rev responsive 
element (RRE), which represents the binding site for the Rev protein, and the 
purine-rich region (polypurine tract, PPT), that provides a second primer for the 
initiation of plus strand DNA synthesis by reverse transcriptase (reviewed by 
Pluta and Kacprzak, 2009). 
The 5’ LTR drives transcription of an initial genome-length RNA that also acts as 
an mRNA for translation of the viral Gag and Pol proteins. The Gag precursor 
protein (Pr55) is proteolytically cleaved by viral protease to yield matrix (MA, 
p17), capsid (CA, p24), nucleocapsid (NC, p7), p6 and two spacer peptides (p1 
and p2). The Pol protein is produced as a Gag-Pol precursor (Pr160) following a -
1 frameshift event, required as the sequences coding for the Gag and Pol proteins 
are in different reading frames. The frameshifting occurs at an approximate rate of 
one Gag-Pol for every twenty Gag molecules synthesized. The Gag-Pol 
polyprotein is cleaved by the same protease resulting in the p6* transframe (TF) 
polypeptide and in three viral enzymes: protease (PR, p11), reverse transcriptase 
with ribonuclease H (RNase H) activity (RT, heterodimer p66/p51 and RNase H, 
p15) and integrase (IN, p31). The initial transcript is also processed into fully 
spliced transcripts encoding the Tat and Rev regulatory proteins, as well as the 
Nef accessory protein. Alternatively, this transcript can be processed into partially 
spliced mRNAs coding for the three other accessory proteins: Vif, Vpu and Vpr. 
These partially processed transcripts also contain the env ORF for envelope 
glycoprotein (Env, gp160) translated thanks to the leaky scanning through vpu 
AUG. Proteolysis of the precursor envelope glycoprotein gp160 by furin cellular 
protease results in the formation of the surface subunit (SU, gp120) and the 
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CXCR4-using (X4) viruses (mixed)] on the basis of the co-receptor usage 
(Whitcomb et al., 2007). Formation of the gp120/co-receptor/CD4 complexes 
triggers refolding of the non-covalently associated transmembrane gp41 protein, 
that inserts an N-terminal hydrophobic fusion peptide into the cellular plasma 
membrane. The gp41 trimer subsequently folds in, to form a six-helix bundle 
which couples the viral and cellular membranes promoting their fusion. Once the 
fusion is initiated, the viral core contents are released into the cytoplasm. The 
positive sense RNA strand is, then, converted into double-stranded DNA by viral 
RT within a large ribonucleoprotein structure, called the reverse transcription 
complex. Reverse transcription requires a specific cellular tRNA annealed to the 
PBS for the initiation of cDNA synthesis. In the case of HIV-1, tRNALys3 is 
preferentially selected during virus assembly. The nascent viral DNA binds 
several viral and cellular proteins to produce the so-called preintegration complex 
(PIC) that is actively imported into the nucleus through nuclear pores. In the 
nucleus, the linear provirus cDNA integrates into the DNA of the host cell. Viral 
IN circularizes the provirus at the att repeats and plays a crucial role in its 
integration into host cell DNA via recombination between the att repeats and the 
integration site. It was shown that integrase is the principal viral determinant of 
integration specificity, by virtue of its binding with the LEDGF/p75 cellular 
protein, that mediates the preferential integration target site selection within active 
transcriptional units (Maertens et al., 2003; Engelman et al., 2008). Once the 
proviral DNA is integrated, the late phases of the lentiviral life cycle take place. 
The LTRs, capping the ends of the viral genome, regulate transcription and 
polyadenylation of viral mRNAs. The LTR at the 5’ end of the genome acts as a 
combined enhancer and promoter for transcription by host cell RNA polymerase 
II. The LTR at the 3’ end of the genome stabilizes these transcripts by mediating 
their polyadenylation. Basal promoter activity by the 5’ LTR is minimal in the 
absence of the Tat transactivator. Initial transcription in the absence of Tat 
produces viral mRNAs that are multiply spliced into short transcripts. These short 
transcripts encode the Tat, Rev and Nef proteins, that facilitate subsequent events 
in the viral life cycle. Newly synthesized Tat binds to the stem-loop-shaped TAR 
element on the 5’ end of HIV-1 mRNAs, leading to the phosphorylation of the 
carboxy-terminal domain of RNA polymerase II, that results in dramatic 
12 
 
stimulation of transcriptional processivity. Transcription of viral mRNAs begins 
at the first nucleotide of the R region in the 5’ LTR and polyadenylation occurs at 
the last nucleotide of R in the 3’ LTR. Meanwhile, Rev binds to the RRE element 
on the viral transcripts to facilitate nuclear export of singly spliced or non-spliced 
viral transcripts and genome. Singly spliced transcripts encode Env, Vif, Vpr and 
Vpu, whereas non-spliced viral RNAs are used for translation of Gag and Pol and 
as the genomic RNAs for progeny viruses. HIV-1 uses the cellular splicing 
machinery to express its genes. Cellular factors, in concert with both positive and 
negative cis elements within the viral genome, act to promote or repress splicing. 
These cis elements include several splice donor (SD) and acceptor (SA) 
sequences. Exported viral genomes and proteins are assembled at the plasma 
membrane in a series of coordinated events, encompassing Gag dimerization and 
multimerization (thanks to contacts made by the CA, SP1 and NC regions), 
binding of Gag complexes to genomic viral RNA (through the interaction between 
the NC domain and the Ψ signal) and migration of the Gag-RNA complexes, Gag, 
Gag-Pol and Env to the site of assembly. The Gag precursor protein Pr55 plays a 
central role in this process. Indeed, the MA domain of Gag is responsible for 
targeting and association with plasma membrane and it also facilitates envelope 
binding to the site of budding. In addition, Gag-Pol precursor is directed into the 
assembling particle through its interaction with Gag. HIV-1 completes its 
replication cycle by budding through the cellular plasma membrane. In T cells, 
virions are believed to assemble and bud from the so-called lipid rafts, which are 
plasma membrane microdomains enriched in cholesterol and sphingolipids. Virus 
egress takes advantage of the interactions between viral late domains in the p6 
peptide of Gag and the cellular components of the endosomal sorting complex 
required for transport (ESCRT), that allow viral and cellular membrane separation 
(Göttlinger et al., 1991; Strack et al., 2002, 2003). Initially, virus particles are 
released from the infected cell in an immature form. During or shortly after virus 
budding, the protease, activated by Gag-Pol multimerization, cleaves the Gag and 
Gag-Pol polyproteins. This process takes place as an ordered cascade of cleavage 
reactions, leading to the formation of the inner core of the virions, the 
development of the conical-shaped core shell and the conversion of the immature 
virus particle into an infectious virus (reviewed by Ganser-Pornillos et al., 2008). 
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After initial contact, the virus is transported into the secondary lymphoid organs, 
where infection of CD4+ cells (T lymphocytes and monocytes/macrophages) 
occurs. A phase of rapid viral replication follows, during which viral load 
(viremia and the number of infected cells) increases exponentially in blood and in 
lymphoid organs. This phase of primary infection can be asymptomatic; however, 
30-70% of infected individuals experience an acute syndrome, characterized by 
fever, fatigue, lymphoadenomegaly, maculo-papular cutaneous eruption, and, in a 
few cases, neurological involvement. The rapid viral replication stimulates a 
robust immune response, with the generation of neutralizing antibodies and 
cytotoxic T lymphocytes (CTLs), recognizing and destroying the infected cells. 
This response curtails viral infection and markedly decreases viral load in 
patients. However, in contrast to other acute viral diseases, the virus is not 
eradicated from the organism, since it persists in its integrated, proviral DNA 
form in a reservoir of latently infected cells. These are mainly CD4+ T memory 
lymphocytes (CD45+ R0+), which do not proliferate and are metabolically 
inactive. Since these cells do not transcribe the viral genome, no viral protein is 
expressed and the cells remained unrecognized by the CTLs. A long period thus 
begins in which the virus replicates in metabolically active cells (activated T 
lymphocytes and macrophages), but remains latent in inactive cells. The immune 
system is unable to eradicate the infection, partly because of this latency 
phenomenon and partly because the replicating fraction of the virus continuously 
mutates its sequence and, thus, generates mutants escaping neutralizing antibodies 
and CTLs. These mutant variants are continuously selected in vivo upon pressure 
of the immune response. This condition can last several years, in which the patient 
is asymptomatic or paucisymptomatic, but shows relevant levels of plasma 
viremia and is, thus, infective. This asymptomatic phase of the disease eventually 
exhausts the immune function, mainly because of the progressive decline in the 
CD4+ T cells, which are the main targets for infection. Since these cells provide 
an essential helper function to both antibody production and CTL function, the 
patients progressively become immunodeficient. This acquired immunodeficiency 
syndrome (AIDS) phase is characterized by recurrent infections, due to normally 
non-pathogenic microorganisms, and by the development of malignant tumors. 
The infectious diseases of AIDS patients include recurrent pulmonitis, cerebral 
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toxoplasmosis, cryptosporidiosis, cutaneous infections and meningitis. The 
malignant tumors of these patients include Kaposi’s sarcoma and non-Hodgkin’s 
lymphomas. In the absence of therapy, the median life expectancy after HIV-1 
infection is about 9.5 years (Vergis et al., 2000; Ho and Bieniasz, 2008, Cohen, 
2011). 
The treatment of HIV-1 infection was revolutionized in the mid-1990s by the 
development of inhibitors of the viral reverse transcriptase and protease enzymes, 
and by the introduction of drug regimens that combined these agents to enhance 
the overall efficacy and durability of therapy. The advent of combination therapy, 
also known as highly active antiretroviral therapy (HAART), was seminal in 
reducing the morbidity and the mortality associated with HIV-1 infection and 
AIDS (Arts and Hazuda, 2012). The U.S. Food and Drug Administration 
approved 37 antiretroviral drugs for the treatment of HIV infection up to October 
2013. These include nucleoside reverse transcriptase inhibitors (NRTIs), non-
nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), 
fusion inhibitors, entry inhibitors (CCR5 co-receptor antagonist) and integrase 
strand transfer inhibitors (www.fda.gov). Typical HAART regimens include a 
backbone of two NRTIs and a base of either a PI or NNRTI. New classes of drugs 
like entry inhibitors and integrase inhibitors have also emerged in clinical practice 
(Margolis at al., 2013). Combination antiretroviral therapy dramatically 
suppresses viral replication and reduces the plasma HIV-1 viral load, resulting in 
a significant reconstitution of the immune system. With proper adherence, 
HAART can suppress viral replication for decades, increasing the life expectancy 
of the HIV-infected individual (Arts and Hazuda, 2012). 
However, HAART cannot eliminate HIV-1 infection. Cessation of even 
prolonged HAART regimens results in viral load rebound to pre-therapy levels, 
indicating the inability of chemotherapy to eradicate HIV-1 infection. This failure 
has been attributed to the presence of a long-lived, stable population of latently 
infected cells that are not eliminated by the antiviral treatment, since this 
treatment only targets the replicating fraction of the virus. Several of these cells 
are long-lived memory T cells that have an integrated proviral DNA, that is kept 
in a transcriptionally silent state. The persistence of latent HIV-1 reservoirs is at 
present the principal barrier to the complete eradication of HIV-1 in patients 
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treated by HAART, making HIV-1 infection a chronic disease for which there is 
currently no functional or sterilizing cure (Stevenson, 2013). The prospect of 
maintaining therapy for the lifetime of a patient represents a major hurdle. In 
addition, HAART is still fraught with important long-term toxicity, including an 
increased cardiovascular risk. This is mainly due to the use of HIV protease 
inhibitors, which determine hyperlipidemia and, thus, increased coronary risk. 
Furthermore, the effect of therapy can be impaired by nonadherence, poor drug 
tolerability and interactions among antiretroviral agents and other medications, 
that decrease optimal drug levels. Each of these can lead to virologic failure and 
the evolution of drug resistance. For all antiretroviral drug classes, drug resistance 
has been documented in patients failing therapy, as well as in therapy-naive 
patients infected with transmitted, drug-resistant viruses. Considering that the 
virus continues to evolve and escape, with even the most effective therapies, new 
HIV-1treatments will always be needed (Arts and Hazuda, 2012). 
 
4.4 Gene therapy of HIV-1 infection 
 
Gene therapy has potential as an alternative or complementary treatment strategy 
to HAART for HIV-infected individuals. Gene therapy can contribute to the 
treatment of HIV-1 infection by at least three different modalities: by rendering 
the target cells resistant to infection or viral replication (intracellular 
immunization), targeting either the viral proteins or the viral RNAs; by inducing 
the selective activation of suicide or antiviral genes upon HIV-1 infection or by 
activating the immune system to recognize and destroy the infected cells. 
The intracellular immunization approach intends to make HIV-1 target cells 
resistant to viral infection by introducing anti-HIV-1 genes (Baltimore, 1988). 
Over the past 20 years, researchers have developed numerous gene-based reagents 
capable of inhibiting HIV-1 infection by intracellular immunization (Figure 4.3). 
These have included the expression of intracellular antibodies to viral proteins; 
antisense RNAs, that inhibit reverse transcription, viral gene expression, 
processing or translation of HIV-1 RNAs; mutant HIV-1 structural or regulatory 
genes, with dominant repressor activity (including Rev, Gag and Tat); RNA 
decoys, that inhibit HIV-1 transcription (multimeric TAR) and processing 
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(multimeric RRE); ribozymes, to catalytically cleave and inactivate the various 
HIV-1 RNA species, and small interfering RNAs (siRNAs), that downregulate 
HIV-1 RNA sequences (reviewed by Hoxie and June, 2012). A different strategy 
targeting HIV-1 entry was explored by Egelhofer and colleagues (Egelhofer et al., 
2004), that developed an HIV-1 fusion inhibitor, termed C46, derived from the C-
terminal domain of HIV gp41. C46 can be stably expressed into virus target cells, 
where it blocks HIV fusion by binding to gp41. In addition, a more recent novel 
approach to disrupt the CCR5 co-receptor gene was developed by using 
engineered zinc finger nuclease proteins (ZFNs) (Perez et al., 2008; Holt et al., 
2010; Wilen et al., 2011; Li et al., 2013). ZFNs are comprised of custom-made 
zinc finger DNA binding domains fused to an endonuclease domain that generates 
a double-strand break at a specific DNA target site. When these double-strand 
breaks are repaired, deletions and insertions can be introduced at the site of 
cleavage through a non-homologous end joining (NHEJ) cellular DNA repair 
mechanism. 
Furthermore, studies of the underlying mechanisms of host restriction factors are 
expanding the repertoire of possible molecular gene therapy approaches against 
HIV-1. In this context, attention has been devoted to the TRIM5α protein. 
TRIM5α is a cellular protein that plays an important role in the restricted host 
range of HIV-1 (Stremlau et al., 2004). Indeed, TRIM5α of old world monkeys, 
such as rhesus macaques, inhibits HIV-1 infection by disrupting the uncoating of 
the viral capsid in the cytoplasm, while the human orthologue is permissive. Only 
one or two aminoacid differences between the human and rhesus TRIM5α are 
responsible for the opposite behavior of the two proteins. These evidences lent 
support for the use of chimeric human-rhesus TRIM5α variants (Anderson et al., 
2009) or engineered human variants to block HIV infection (Sayah et al., 2004; 
Pham et al., 2010; Neagu et al., 2009, Chan et al., 2012). All of these anti-HIV 
genes mediated efficient HIV-1 inhibition in various experimental settings and 
some of these were also tested in clinical trials. Other host HIV-1 restriction 
factors that could be potentially utilized as gene therapy reagents are 
APOBEC3G, APOBEC3F and Tetherin (reviewed by Kitchen et al., 2011). The 
APOBEC3 proteins are packaged in the virion and block reverse transcription by 
deaminating nascent viral cDNA, while Tetherin prevents viral budding from the 
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The most attractive target cell for anti-HIV gene therapy is represented by HSCs, 
as they are capable of self-renewal and differentiation into all hematopoietic 
lineages. Gene therapy approaches that introduce protective genes against HIV-1 
via HSCs can continuously produce their antiviral genes in all differentiated cells, 
including HIV-1 target cells, such as CD4+ T lymphocytes, macrophages and 
dendritic cells. Successful replacement of a patient’s immune system by gene 
modified HIV-1 protected cells may have the potential to minimize viral load, as 
well as to reduce reservoirs of infected and latently infected cells. Newly 
differentiated protected cells may prevent viral production and spread from 
persistently infected cells, and may allow the functional restoration of the 
damaged immune system. If successful, gene therapy through stem cells could 
free patients from lifelong daily medications (Kitchen et al., 2011). 
A typical protocol for ex vivo HSCs gene therapy requires cells to be isolated from 
the bone marrow or mobilized by several rounds of G-CSF (granulocyte colony 
stimulating factor) injection. The stem cells are collected by apheresis and the 
CD34+ cells enriched. Following culture ex vivo in conditions that stimulate cell 
proliferation, the cells are exposed to a retroviral vector expressing the therapeutic 
gene(s) and, then, infused back into the patient after a few days. Infusion usually 
takes place following administration of a pharmacological conditioning regimen, 
that eliminates the endogenous bone marrow progenitors and favors engraftment 
of the transplanted cells. If the gene-corrected cells have a selective growth 
advantage compared to the unmodified cells, full reconstitution of the immune 
cell compartments is obtained even from a few engrafted transduced progenitors 
cells, and this may occur without conditioning (Naldini, 2011). A potential 
drawback of this procedure is that manipulation of HSCs is technically 
challenging, as these cells are difficult to be maintained in culture without losing 
viability or undergoing differentiation (Hoxie and June, 2012) (Figure 4.4).  
Considering that HIV infection causes a severe depletion of CD4+ T lymphocytes, 
genetic modification of T cells to inhibit viral replication cycle offers an 
alternative to HSC manipulation. However, the issue of whether the addition of 
engineered CD4+ T-cell may preserve their immune function allowing long-term 
persistence is challenging. On the other hand, mature T cells appear to be less 
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4.6 HIV-1 gene therapy trials 
 
Several anti-HIV-1 gene therapy protocols have been tested in clinical trials. Most 
clinical trials were phase I studies aimed at evaluating the safety and feasibility of 
anti-HIV-1 gene-transduced autologous CD4+ T lymphocyte and hematopoietic 
stem/progenitor cell transplantation in patients. In early trials, dominant negative 
proteins (RevM10), RRE decoy, or anti-HIV-1 ribozyme were introduced into 
patient’s CD34+ cells with Moloney murine leukemia virus (MLV)-based 
gammaretroviral vectors. All of these phase I clinical studies demonstrated safety 
and feasibility of the procedures. Gene transfer and stem cell transplantation were 
well tolerated and no significant adverse events have been observed. In all of 
these trials there were detectable levels of anti-HIV-1 gene expressing cells in 
patients; however, the gene marking levels were too low to achieve clear 
therapeutic benefits (reviewed by Kitchen et al., 2011). 
Mitsuyasu and colleagues reported the first phase II clinical trial of an anti-HIV-1 
gene therapy approach in 2009 (Mitsuyasu et al., 2009). Here the investigators 
used the MLV-based OZ1 vector containing a gene encoding a ribozyme targeting 
the HIV-1 overlapping vpr and tat reading frames. In both phase I and II clinical 
trials, autologous CD34+ HSCs were transduced and administered without the 
subject undergoing myeloablation or any form of bone marrow conditioning. The 
phase I trial reported no serious adverse events related to the gene transfer process 
or the gene transfer product, and the transgene was detected in peripheral blood 
cells and bone marrow cells of some patients up to 3 years after a single infusion 
of the genetically modified cells. In phase II trial, which enrolled 74 subjects, 
ribozyme DNA and RNA were detectable in 94% of patients, but gradually 
declined to 7% of patients 100 weeks following treatment. Although the levels of 
ribozyme DNA and RNA were low, lower viral loads and higher CD4+ cell 
counts were observed (Mitsuyasu et al., 2011). Overall, these studies 
demonstrated a proof of concept that anti-tat/vpr ribozyme transduced autologous 
HSCs transplanted in humans is safe and has a capability to produce gene 
modified cells in a large numbers of human subjects (Kitchen et al., 2011). 
The first anti-HIV-1 gene therapy clinical study employing a lentiviral vector 
expressing a combination of antiviral molecules was described by DiGiusto and 
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colleagues in 2010 (DiGiusto et al., 2010). Four AIDS lymphoma patients 
undergoing treatment with transplanted HSCs were also given gene-modified 
CD34+ hematopoietic progenitor cells expressing three RNA-based anti-HIV 
moieties (tat/rev short hairpin RNA, TAR decoy, and CCR5 ribozyme). In vitro 
analysis of these engineered cells showed no differences in their hematopoietic 
potential compared with untransduced cells. Ethical study design required that 
patients were transplanted with both gene-modified and unmanipulated 
hematopoietic progenitor cells, obtained from the patient by apheresis. 
Transduced cells were successfully engrafted in all four infused patients by day 
11, and there were no unexpected infusion-related toxicities. Persistent vector 
expression in multiple cell lineages was observed at low levels for up to 24 
months, as was expression of the introduced siRNA and ribozyme. These results 
support the development of a combinatorial RNA-based cell therapy platform for 
HIV-1. 
Another approach to HIV-1 therapy based on gene transfer employed VRX496, an 
HIV-1-based lentiviral vector expressing a 937-base antisense gene 
complementary to HIV-1 env. In this context, transgene transcription is under the 
control of the native HIV-1 LTR, thus infection with HIV-1 and the resulting Tat 
expression transactivate VRX496 to up-regulate the antisense RNA expression. 
Because VRX496 retains HIV-1 cis-acting elements required for replication, the 
vector can potentially be mobilized by HIV-1 infection and spread to new CD4+ 
T cells. Levine and co-workers reported results after a single infusion of 
VRX496-containing CD4+ T cells in patients failing HAART (Levine et al., 
2006). The infusion was safe and associated with improved CD4+ T cell counts, 
persistent gene transfer and no evidence of insertional mutagenesis. Given these 
results, investigators hypothesized that multiple infusions of gene-modified cells 
in earlier stage patients with well-controlled viremia would improve the 
persistence of VRX496 and enhance the therapeutic effect. Results of this latter 
clinical trial reported the safety and tolerability of multiple infusions of vector-
modified autologous CD4+ T cells. A significant decrease in viral load set point 
was observed after discontinued antiretroviral therapy. In addition, it was found 
that expression of the antisense sequence in gene-modified cells exerted genetic 
pressure on HIV-1, causing production of replication-impaired virus. The 
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engraftment half-life of vector-modified CD4+ T cells in the blood was 
approximately 5 weeks, with stable persistence in some patients for up to 5 years. 
No evidence of clonal selection of vector-transduced T cells or integration 
enrichment near oncogenes was detected. This early-phase study pointed out that 
gene-modified T cells have the potential to decrease the fitness of HIV-1 and 
conditionally replicative lentiviral vectors have a promising safety profile in T 
cells (Tebas et al., 2013). 
These and other trials have shown the safety of the procedure and of the anti-HIV-
1 agents themselves, as well as the feasibility of the approach in which autologous 
HSCs and/or CD4+ T cells are taken from the subject, genetically manipulated 
and given back to the subject. Areas for further focus appear to be maximizing the 
number of the infused gene-tranduced cell; maximizing the engrafment, 
proliferation and differentiation of this genetically modified cells, possibly 
incorporating partial myeloablation; increasing the effectiveness of the used anti-
HIV-1 gene(s) and automation of the cell processing procedure (Mitsuyasu et al., 
2011). 
 
4.7 RNA interference as an anti-HIV-1 therapeutic 
 
Since the first description of RNA interference (RNAi) in 1998 (Fire et al., 1998), 
it has rapidly become one of the methods of choice for gene function analyses and 
it is being exploited for therapeutic applications. To date, preclinical studies 
indicate that RNAi is the most potent RNA-based inhibitory mechanism available 
for therapeutic application (Hoxie and June, 2012). 
HIV-1 was one of the first infectious agents targeted by RNAi as a result of the 
virus relatively well-understood life cycle and pattern of gene expression. RNAi 
induction has been shown to be highly effective in inhibiting HIV-1 (Lee et al., 
2005; Liu et al., 2007; Sano et al., 2008). RNAi triggers have been used to target 
virtually all the HIV-encoded RNAs in cell lines, including tat, rev, gag, pol, nef, 
vif, env, vpr and the LTRs. Indeed, each step in the replicative cycle of HIV-1 
could be considered as target for RNAi-based therapeutic intervention. Other 
studies have shown a host of other viruses, including the hepatitis B virus, 
hepatitis C virus, poliovirus and respiratory syncytial virus to be targeted by 
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RNAi (reviewed by Leonard and Schaffer, 2006). However, it has been shown 
that knockdown efficacy of an RNAi effector varies according to its sequence and 
target site on RNA and hence results in limited number of highly potent 
therapeutic agents (Tyagi et al., 2011). 
RNAi is an evolutionary conserved mechanism that triggers sequence-specific 
inhibition of complementary mRNAs in eukaryotes. In mammals, RNAi is a post-
transcriptional gene silencing mechanism that functions to regulate gene 
expression via small hairpin-like double stranded RNA (dsRNA) molecules called 
microRNAs (miRNAs) (Figure 4.5). More than 1000 human miRNAs have been 
identified, which are estimated to regulate the expression of at least 30% of 
human genes (Liu and Berkhout, 2011). miRNAs are expressed from polymerase 
II promoters as primary miRNA transcripts (pri-miRNAs), forming distinctive 
imperfect hairpin structures. Pri-miRNAs are first processed by a Drosha complex 
cleaving ~22 bp back from the stem-loop junction, to release a 60-80 nucleotide 
hairpin (pre-miRNA) and, then, exported from the nucleus to the cytoplasm by the 
nuclear Exportin-5 protein. In the cytoplasm, Dicer next cleaves from the opposite 
end, removing the loop to release a small RNA duplex of ~21 bp with 
characteristic 2-nt 3’ overhangs (the mature miRNA). The duplex is then loaded 
into the RNA induced silencing complex (RISC) and unwound into the effector 
guide strand and the passenger strand. The guide strand is selected according to 
thermodynamic stability at the ends of the duplex. This strand directs RISC to 
bind target RNA within the 3’ untranslated region, resulting in translational 
repression, mRNA destabilization or a combination of both. Near-perfect base 
pairing of the miRNA with the mRNA results in cleavage-mediated inactivation 
of the target mRNA. The targeted mRNA is translocated to cellular processing 
(P)-bodies where storage, de-adenylation, de-capping and degradation take place 
(McIntyre et al., 2011; Liu and Berkhout, 2011). In invertebrates and plants, 
RNAi provides an innate defence mechanism against invading RNA viruses, as 
the introduction of dsRNAs into the cells of these organisms leads to the 
processing of the dsRNA molecules into siRNAs that serve as guides for 
enzymatic cleavage of complementary RNAs (Yu et al., 2002). 
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RNAi can be co-opted by delivering synthetic siRNAs duplexes of 19-21 bp, that, 
mimicking the mature miRNAs, are loaded directly into RISC, to mediate post-
transcriptional silencing of their target (McIntyre et al., 2011). A constant supply 
of siRNAs is required to combat chronic infections like HIV-1, thus much of the 
anti-HIV RNAi research is focused on the development of RNAi triggers that can 
be stably expressed within target cells as gene therapy strategy (Schopman et al., 
2010). To this end, a short hairpin RNA (shRNA) consisting of the sense and 
antisense sequences of an siRNA connected by a loop of unpaired nucleotides can 
be expressed by viral vectors (Figure 4.6A). Following transcription, shRNAs are 
exported to the cytoplasm and processed by Dicer and, finally, they engage the 
RISC complex via the normal miRNA biogenesis pathway. shRNA design often 
occurs by the addition of a loop to an optimally designed siRNA core. The hairpin 
loop may be an important determinant of the shRNA activity (Schopman et al., 
2010). The most extensively adopted loop sequence is a 9-mer nucleotide 
sequence (TTCAAGAGA) published by Brummelkamp and co-workers in 2002 
(Brummelkamp et al., 2002). 
Expression of shRNAs is mostly driven by RNA polymerase III promoters, 
including the small nuclear RNA U6 promoter, the RNase P RNA H1 promoter 
and tRNA promoters, because of their natural function in the production of small 
cellular transcripts (Liu and Berkhout, 2011). These promoters are compact, 
active in many tissues, strong and usually generate a huge amount of transcription 
products that are presumably processed directly by Dicer. Another advantage of 
using polymerase III promoters is that the sequence of the generated siRNA can 
be controlled because the transcription starts from the +1 position of the promoter 
transcription unit and termination occurs within a stretch of uracils in the 
terminator sequence, facilitating the generation of double stranded shRNA with 3’ 
overhangs, that is essential for Dicer processing (Manjunath et al., 2009).  
The original shRNA design has been further optimized by embedding the hairpins 
in a microRNA-like context via inclusion of structural motifs of pri-miRNAs 
(Figure 4.6B). In this approach, an siRNA is inserted at the location of the mature 
miRNA in a specific pri-miRNA scaffold. Artificial miRNAs are usually 
transcribed from an RNA polymerase II promoter, that is the natural promoter of 
most miRNA genes. The use of RNA polymerase II promoters has some benefits 
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in that regulatable and tissue-specific variants exist, yet inducible RNA 
polymerase III systems have also been described (Liu and Berkhout, 2011). 
 
 
 
Figure 4.6. Artificial RNAi effectors. (A) Short hairpin RNAs (shRNAs) composed of a perfectly 
complementary stem with a small hairpin loop are commonly expressed from RNA polymerase III 
promoters, because they allow precise initiation and termination of transcription. (B) Artificial 
miRNAs resemble the natural miRNAs with their characteristic features, including loops, internal 
mismatches, bulges and flanking sequences (Adapted from Liu and Berkhout, 2011). 
 
4.8 Combinatorial RNAi strategies 
 
The use of a single anti-HIV-1 gene may not be sufficient to protect cells long-
term from infection, due to the high mutation rate of HIV-1. Indeed, development 
of viral resistance is a common setback with HIV-1 therapies, because of the 
generation of viral escape mutants (Zhou and Rossi, 2011). Thus, similar to 
combination approaches with small-molecule drugs, effective gene therapy 
applications against HIV-1 disease will require a combination of multiple reagents 
directed against the virus (Scherer and Rossi, 2011).  
A number of different escape routes have been described when inhibiting HIV-1 
replication by means of RNAi-based approaches. Firstly, a point mutation in the 
target sequence can reduce the complementarity with the shRNA inhibitor and, 
thereby, abolish the RNAi-suppression. Secondly, the complete or part of the 
target region could be deleted, when non-essential viral genes are targeted. 
Thirdly, resistance-causing mutations were observed outside the target region. 
These mutations elicit a structural change in the HIV-1 mRNA, thus making the 
target sequence inaccessible for the RNAi-machinery (Eekels et al., 2011). 
In silico studies analyzing the impact of anti-HIV-1 gene therapy provided 
evidence that four or more shRNAs with targets within viral genes can effectively 
suppress the spread of infection, while constraining the development of resistance 
(McIntyre et al., 2009). There are several different methods for co-expressing 
A B
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multiple RNAi triggers, including: different expression vectors; multiple shRNA-
expression cassettes from a single vector; long hairpin RNAs (lhRNAs); 
extended-short hairpin RNAs (e-shRNAs) and multiple miRNA-embedded 
shRNAs (Figure 4.7).  
The multiple expression cassette strategy is perhaps the most promising and has 
been used successfully in transient expression studies with cassette combinations 
ranging from 2 to 7 (ter Brake et al., 2006; McIntyre et al., 2009; Centlivre et al., 
2013). However, different promoters should be used, as the presence of repeated 
sequences might cause recombination within the vector genome during the 
transduction process, resulting in deletion of one or more cassettes (ter Brake et 
al., 2008).  
Alternatively, lhRNAs or e-shRNAs expressing multiple effective siRNAs from a 
single promoter can mediate a durable HIV-1 inhibition (Liu et al., 2007, 2009; 
Sano et al., 2008; Saayman et al., 2008). lhRNAs produce siRNAs targeting 
adjacent mRNA sites, but the siRNA units are not well-defined and have not been 
previously singly tested for knockdown activity (Liu and Berkhout, 2011). By 
contrast, e-shRNAs are based on careful stacking of two or more pre-validated 
siRNAs. Several constrains regulate the design of the e-shRNAs. It has been 
demonstrated that hairpin transcripts have un upper size limit for effective 
production of multiple, functional siRNAs. In general, the hairpins seem to lose 
activity when they get larger than 66 bp. This decrease in siRNA production could 
be due to reduced expression, diminished stability, hampered nuclear export, or 
poor processing into functional siRNAs (Liu et al., 2009). Thus, the design of e-
shRNAs is restricted to the expression of three active siRNAs, because addition of 
a fourth siRNA resulted in a dramatic decrease in hairpin transcript expression. 
Other relevant aspects to be considered are the spacing between the stacked 
siRNAs and their positioning along the hairpin stem. Indeed, on the one hand, the 
exact cleavage site of Dicer is unknown and pilot research is needed to accurately 
stack the siRNA units, such that the proper inhibitors are made upon Dicer 
processing (Liu and Berkhout, 2011). Berkhout and colleagues adopted a 3-mer 
nucleotide spacer sequence between consecutive siRNAs in their successful e-
shRNA design (Liu et al., 2009). On the other hand, it has been shown that the 
siRNAs are produced in a gradient from the base of the hairpin towards the top, 
29 
 
with the most abundant and active one being at the base. This is probably due to a 
reduced Dicer processing towards the hairpin loop (Liu and Berkhout, 2011). 
An alternative combinatorial RNAi strategy is based on the expression of multiple 
siRNAs from a miRNA polycistron. By mimicking a miRNA cluster, multiple 
siRNAs can be expressed from one single RNA polymerase II transcript. This 
approach closely resembles the natural situation where several miRNAs can be 
expressed in a coordinated manner from a single transcriptional unit. Despite the 
many positives results with the microRNA approach, this strategy is not yet 
broadly employed by researchers because of its complex design. For example, the 
flanking sequences, the position of the siRNA insert within the miRNA hairpin, 
the miRNA scaffold and the simultaneous co-expression of another miRNA 
hairpin have all shown to influence RNAi activity (Liu and Berkhout, 2011). 
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cellular genes, it is important to scan for such homologies, as well as to ensure 
that the passenger strand is not loaded to RISC. This latter point can be achieved 
by designing shRNAs with a thermodynamically less stable 5’ end and more 
stable 3’ end, after processing by Drosha and Dicer (Manjunath et al., 2009). 
Secondly, ectopic expression of shRNAs can lead to competition for and possibly 
saturation of endogenous cellular components involved in RNAi. This has been 
shown for exportin-5, the transport carrier that is needed for nuclear export of 
endogenous microRNA precursors. In one study, long-term and sustained 
expression of shRNAs via adeno-associated viral (AAV) vector in the mouse liver 
resulted in a dose-dependent liver injury and led to mortality at high doses of 
expression. This morbidity has been attributed to the saturation of exportin-5 by 
shRNAs, since the liver-derived microRNAs were significantly downregulated in 
these mice (Grimm et al., 2006). Consistent with this, over expression of exportin-
5 could relieve competition with cellular microRNAs (Yi et al., 2005). Another 
study showed that the polymerase III U6 promoter-processed transcripts 
accumulate both in the cytosol and nucleus, indicating that both exportin-5 and 
Dicer might be saturated (Boudreau et al., 2008). Similarly, lentiviral expression 
of large amounts of shRNAs generated from the U6 promoter resulted in toxicity 
in primary human T lymphocytes in vitro, that could be mitigated by lower level 
of expression under the control of H1 promoter (An et al., 2006). Therefore, even 
if potent and sustained shRNA expression is crucial for the successful application 
of RNAi to therapeutic interventions, caution is necessary, as the amount of 
expressed shRNAs can be a critical determinant of whether they are toxic. 
Thirdly, shRNAs can cause cytotoxicity by triggering type I interferon (IFN) 
responses, resulting in non-sequence specific degradation of messages (Snøve and 
Rossi, 2006). Interferon responses can be elicited either through the cytosolic 
dsRNA-activated protein kinase PKR, or the toll-like receptors 3 and 7, that 
recognize RNA on the cell surface or in endosomes. Certain nucleotide motifs 
such as 5’-UGUGU-3’ or 5’-GUCCUUCAA-3’ within siRNAs appear to be 
responsible for the induction of interferon and interleukin production by 
plasmacytoid dendritic cells. Thus, it is important to avoid such motifs in the 
shRNA design (Manjunath et al., 2009). In addition, the risk of IFN response 
induction may increase when dsRNAs longer than 30 bp are introduced in 
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mammalian cells (Manche et al., 1992; Liu et al., 2007). In this regard, it has been 
reported that lhRNAs and e-shRNAs of more than 50 bp, harboring multiple C to 
U (or A to G) mutations within the sense strand, can specifically inhibit gene 
expression, without inducing type I interferon (IFN) pathway. These mutations 
introduce wobble pairings along the stem region of the hairpins, that change their 
thermodynamic properties, allowing them to evade recognition by dsRNA-
binding proteins, such as PKR. In addition, the use of these mutations may have 
several other advantages over perfectly complementary hairpins. For instance, 
mismatches may prevent deletions during plasmid propagation in E.coli, by 
avoiding the formation of stable hairpin structures; facilitate sequencing of the 
hairpins; abrogate RNAi-mediated cleavage of the vector transcripts, triggered by 
siRNAs produced from the hairpins during the packaging reactions, and allow 
more efficient reverse transcription of the vector after transduction (Sano et al., 
2008). 
In summary, although endogenous shRNA expression has tremendous potential, it 
also possesses several intrinsic risks, that could be dangerous. Therefore, the 
importance of carefully designing shRNA constructs, to optimize the dose and the 
exact sequence of siRNAs, cannot be overemphasized (Manjunath et al., 2009). 
 
4.10 Potential molecular targets for anti-HIV-1 RNAi-based therapeutics 
 
A number of criteria have been proposed for developing genetic inhibitors of 
HIV-1 for human clinical trials.  
Firstly, it is important to target sequences that are conserved among different virus 
strains, to reduce the chance of mutant escape (Zhou and Rossi, 2011).  
Secondly, anti-HIV-1 therapeutics that block entry and replication before virus 
integration are considered the best inhibitors, in comparison with the ones 
inhibiting later steps of the viral replication cycle (Scherer and Rossi, 2011). 
Indeed, mathematical modeling has predicted that post-integration inhibitors lead 
to the persistence of cells carrying an integrated provirus, resulting in an 
accumulation of HIV-1 infected cells that could ultimately counteract their 
antiviral effect. By contrast, inhibitors that act before integration, even those with 
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lower potency, are predicted to exert a systemic antiviral effect with the expansion 
of transduced cells capable of resisting HIV-1 infection (Hoxie and June, 2012).  
Furthermore, it may also be beneficial to select target sequences in the early 
spliced mRNAs encoding the early HIV-1 proteins Tat, Rev and Nef. Indeed, an 
early block of viral gene expression will seriously hamper the expression of the 
late structural proteins and virion assembly (Berkhout, 2009). In this context, 
small interfering RNAs designed to destroy the tat/rev transcripts were found to 
be highly effective in viral suppression (Sano et al., 2008).  
In addition, the many cellular factors that support HIV-1 replication cycle can be 
successfully targeted. This alternative RNAi strategy seems attractive because the 
genetic barrier for viral escape may be significantly higher. For instance, HIV-1 
adaptation to another cellular co-factor may be impossible when no alternative 
cellular functions are available (Berkhout, 2009). While hundreds of human genes 
which depletion inhibited either p24 production or viral gene activities have been 
identified, the CCR5 co-receptor remains one of the most promising cellular target 
for anti-HIV-1 therapeutic approaches. Indeed, heterozygous or homozygous 
individuals for a 32-base-pair deletion in the CCR5 gene (CCR5Δ32), that 
prevents CCR5 expression on the cell surface, are slower progressors or resistant 
to HIV-1 infection, respectively (Samson et al., 1996; Scherer and Rossi, 2011; 
Hütter and Ganepola, 2011a). Epidemiological studies of the Caucasian 
population demonstrated that the CCR5Δ32 deletion shows the highest frequency 
of 10-20% among the heterozygous and 1% among the homozygous karyotype. 
On the contrary, this deletion cannot be found in the Asian, Middle East, African 
and the American Indian population (Martinson et al., 1997; Hütter and Ganepola, 
2011b). The absence of any other significant phenotype associated with a lack of 
CCR5 has spurred the development of therapies aimed at blocking the virus-
CCR5 interaction, and CCR5 antagonists have proved to be an effective salvage 
therapy in patients with drug-resistant strains of HIV-1 (Holt et al., 2010). 
Importantly, Hütter and colleagues reported the case of a patient, known as the 
“Berlin patient”, with acute myeloid leukemia, who was cured of AIDS following 
a bone marrow transplant from a donor homozygous for CCR5Δ32. The engrafted 
donor phenotype appears to have conferred long-term control of HIV-1 
replication, as the patient has been off HAART for several years without HIV-1 
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being detected (Hütter et al., 2009; Hütter and Ganepola 2011a; Allers et al., 
2011; Burke et al., 2013). However, the identification of human leukocyte 
antigen-matched CCR5Δ32 homozygous donors for transplantation presents a 
significant logistical barrier to the general application of this approach (Li et al., 
2013). Therefore, various gene therapy approaches to block CCR5 expression are 
being evaluated, including both mature T cells and CD34+ HSCs as target cells. 
Of note, loss of CCR5 in HSCs appears to have no adverse effects on 
hematopoiesis (Holt et al., 2010). 
 
4.11 Biosafety of retroviral and lentiviral vectors as gene delivery systems 
 
The first clinical trial using a lentiviral vector was initiated in 2003 and involved 
the transduction of CD4+ T cells from HIV-1-positive patients to express an 
antisense sequence targeting the HIV-1 env gene (Levine et al., 2006). Lentiviral 
vectors are being successfully used with increasing frequency in human clinical 
trials (Aiuti et al., 2013; Biffi et al., 2013). Nonetheless, as the first retroviral 
vectors developed, MLV-based gammaretroviral vectors have had the longest-
standing and broadest clinical use and have accounted for approximately 20% of 
gene therapy clinical trials worldwide as of January 2012 (McGarrity et al., 2013; 
Naldini, 2011). 
Lentiviral vectors have distinct characteristics that favor their use in delivery and 
long-term gene expression in human clinical trials. These include the ability to 
accommodate large gene inserts and to transduce both dividing and nondividing 
cells, the high levels and the prolonged duration of transgene expression 
(McGarrity et al., 2013). On the contrary, gammaretroviral vectors are known to 
be prone to silencing of expression by DNA methilation, that specifically targets 
the LTR sequences. Moreover, for integration to occur, gammaretroviral vectors 
require cells to enter division shortly after infection, thus imposing the need for 
prolonged culture under conditions of active proliferation. This requirement may 
become a severe hurdle when ex vivo culture is detrimental to the maintenance of 
relevant stem cell properties and may cause differentiation, as it has long been the 
case with HSCs (Naldini et al., 2011).  
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Insertional genotoxicity is another important issue to consider when using an 
integrating vector for gene therapy purposes. Indeed, insertions could give rise to 
dominant gain-of-function mutations, such as the activation of proto-oncogenes 
flanking an insertion site, or loss-of-function mutations in tumor suppressor genes. 
These events are more likely in gammaretroviral vectors, which have a bias for 
integration near promoters of active genes (Bushman et al., 2005; Montini et al., 
2009; Sharma et al., 2013). Several leukemia cases have been described in two 
SCID-X1 gene therapy trials that employed a gammaretroviral vector (Hacein-
Bey-Abina et al., 2003a,b; Gaspar et al., 2011). In all these patients, the 
therapeutic vector integrated near proto-oncogenes and altered their expression, 
thereby promoting clonal T cell proliferation (Hacein-Bey-Abina et al., 2008). As 
opposed to MLV, lentiviruses tend to integrate into intronic regions of genes, 
without any bias towards insertion near promoters (De Palma et al., 2005; Montini 
et al., 2006; Zhou et al., 2010; Cattoglio et al., 2010; Cartier et al., 2012). In 
addition, the natural history of HIV-1 shows that, despite an overwhelming 
viremia in HIV-1 infected patients, especially in the first weeks of infection, 
where approximately 1-10x109 virus particles are produced in patients per day, 
there is no single report of a lentivirus-induced tumor (McGarrity et al., 2013). 
Montini and coworkers exploited HSCs from tumor-prone mice to assess the 
oncogenicity of prototypical gammaretroviral and lentiviral vectors (Montini et 
al., 2006). Results provided evidence that gammaretroviral vectors triggered dose-
dependent acceleration of tumor onset. Insertions at oncogenes and cell-cycle 
genes were enriched in early-onset tumors, indicating cooperation in 
tumorigenesis. By contrast, tumorigenesis was unaffected by lentiviral vectors and 
did not enrich for specific integrants, despite the higher integration load and 
robust expression of lentiviral vectors in all hematopoietic lineages. These data 
demonstrated that lentiviral vectors have low oncogenic potential, highlighting a 
major rationale for application to gene therapy (Montini et al., 2006). The use of 
SIN LTRs in the last generation lentiviral vectors further reduces the chance of 
insertional genotoxicity, thanks to the deletion of enhancer and promoter elements 
comprised within the U3 region of the LTR (Naldini, 2011). 
MLV-based retroviral vectors present an additional potential safety problem: the 
generation of replication-competent retroviruses during vector production. This 
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event may occur following recombination during reverse transcription between 
the vector RNA and passively incapsidated gag/pol and env RNA sequences 
within the vector particle. This is a point of particular concern when the vector 
stock is destined for a clinical trial. In contrast, and despite extensive production 
and thorough testing of HIV-1 derived vectors, the presence of replicative HIV-1 
in lentivector stocks has never been described (reviewed by Di Nunzio et al., 
2012). 
Although these evidences on the safety of lentiviral vectors are encouraging, 
quantitative analysis awaits the results of the safety monitoring of patients who 
have received lentiviral vectors in the setting of human clinical trials (McGarrity 
et al., 2013). 
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5. AIM OF THE STUDY 
The overall goal of this research project is to explore the use of genetic medicine 
to immunize hematopoietic stem cells (HSCs) harvested from HIV-1-positive 
patients against viral infection. In this context, patients affected by AIDS-related 
lymphoma (ARL) offer a unique opportunity to evaluate anti-HIV-1 gene therapy 
strategies in an ethically acceptable clinical setting, as they often undergo HSC 
transplantation. Once infused back into the patients, the genetically modified 
HSCs would build up an HIV-1-resistant lymphohematopoietic system that could 
lead to a significantly reduced viral load with stable and complete remission of the 
underlying lymphoid malignancy.  
Starting from these considerations, this study is aimed to develop lentiviral 
vectors expressing multiple siRNAs interfering with the virus life cycle at 
different steps and to test their efficacy in human primary cells, including CD4+ T 
lymphocytes and macrophages. The siRNA targets we selected include the CCR5 
cellular gene and the tat, rev and vif viral genes. In order to optimize vector 
design, we compared the antiviral activity and the safety of alternative strategies 
used for multiple siRNA delivery and tested the activity of different promoters. 
This study would contribute to the identification of new anti-HIV-1 combinatorial 
platforms that, once shown to be effective and safe in vivo, may be next in line for 
clinical testing. 
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6. MATERIALS AND METHODS 
  
6.1 Vector construction 
 
The human U6 and 7SK polymerase III promoters were amplified from 293T and 
HeLa genomic DNA, respectively, flanked by EcoRI and MluI sites [U6 promoter 
primers: 5’-GAATTCAAGGTCGGGCAGGAAGAGGGCCTA-3’ and 5’-
ACGCGTGCACGGTGTTTCGTCCTTTCCACA-3’ (GenBank: X07425.1); 7SK 
promoter primers: 5’-GAATTCCTGCAGTATTTAGCATGCCCCACC-3’ and 
5’-ACGCGTCCGAGGTACCCAGGCGGCGCACAA-3’ (GenBank: X05490.1)]. 
The H1 RNA polymerase III promoter was derived from the pLVTHM vector 
(Wiznerowicz and Trono, 2003), digested with EcoRI and MluI.  
To obtain the shCCR5, the shvif and the scrambled sequence, two complementary 
DNA oligonucleotides flanked by MluI and ClaI sites were annealed and cloned at 
EcoRV site of the pBluescript II KS plasmid (Stratagene). Sequences of the 
forward oligonucleotides were as follows: shCCR5 5’-
GAGCAAGCTCAGTTTACACCTTCAAGAGAGGTGTAAACTGAGCTTGCT
CTTTTT-3’ (Liang et al., 2010); shvif 5'-
GTTCAGAAGTACACATCCCTTCAAGAGAGGGATGTGTACTTCTGAACT
TTTT-3' (Lee et al., 2005); scrambled 5’-
GAGCAAGCTCTCGTTACACCTTCAAGAGAGGTGTAACGAGAGCTTGC
TCTTTTT-3’ (Liang et al., 2010). The shRNA sequences feature a loop situated 
between the sense and the reverse complementary sequences (underlined) and a 
polyT terminator at the 3’ end. The scrambled control sequence contains three 
mismatched nucleotides as compared to the shCCR5 (bold).  
To obtain the lhRNA and the e-shRNA sequences a two-step PCR approach was 
undertaken. The first PCR was carried out with the same forward primer 
employed to amplify the U6 promoter and a reverse primer specific for either the 
lhRNA or the e-shRNA. A plasmid containing the U6 promoter and 153 nt of the 
downstream snU6 RNA gene was used as a template. Sequences of the reverse 
primers were as follows: lhRNA 5’-
TCTCTTGAAGAGAAACTTGATAAGTCTAACTGTTCTAATGAACTCTTCA
TCGCTATCTCCGCACGCGTAAACAGAAAAACAA-3’; e-shRNA 5’-
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TCTCTTGAAGGGATGTATACTTCTAAACATACTCCACTTCTTCCTACCA
TGTGGGTATAAACTAAGCTTACTCACGCGTAAACAGAAAAACAA-3’. 
These primers are complementary to the last 20 nt of the snU6 RNA gene and to 
the sense and the 9-nt loop of the respective hairpin. MluI site was inserted 
between the end of the snU6 gene and the first nucleotide of the hairpin, to 
facilitate subsequent cloning. PCR conditions included 1 min at 94°C, 1 min at 
55°C and 1 min at 72°C for 30 cycles. One or 0.5 µl of this reaction were used as 
a template for a second PCR step with the U6 forward primer and the following 
reverse primers: lhRNA 5’-
ATCGATAAAAAGCGGAGACAGCGACGAAGAGCTCATCAGAACAGTCA
GACTCATCAAGCTTCTCTCTCTTGAA-3’; e-shRNA 5’-
ATCGATAAAAAGAGCAAGCTCAGTTTACACCCACATGGCAGGAAGAA
GCGGAGTATGTTCAGAAGTACACATCCCTCTCTTGAAA-3’. These 
primers harbour sequences complementary to the 9-nt loop appended to the 
antisense strand of the respective hairpin, the polymerase III terminator sequence 
and the ClaI site. PCR to obtain the lhRNA was carried out following the same 
conditions described above, while amplification to produce the e-shRNA was 
performed as follows: 40” at 98°C, 1 min at 55°C and 1 min at 72°C for 30 cycles. 
The PCR fragments [including the full-length sequence of either the lhRNA: 5’-
GCGGAGATAGCGATGAAGAGTTCATTAGAACAGTTAGACTTATCAAGT
TTCTCTTCAAGAGAGAGAAGCTTGATGAGTCTGACTGTTCTGATGAGC
TCTTCGTCGCTGTCTCCGCTTTTT-3’ (Sano et al., 2008), or the e-shRNA: 5’-
GAGTAAGCTTAGTTTATACCCACATGGTAGGAAGAAGTGGAGTATGTT
TAGAAGTATACATCCCTTCAAGAGAGGGATGTGTACTTCTGAACATAC
TCCGCTTCTTCCTGCCATGTGGGTGTAAACTGAGCTTGCTCTTTTT-3’] 
were directly cloned into the EcoRV site of the pBluescript II KS plasmid.  
The Pol III promoter (i.e. U6, 7SK or H1) was inserted immediately upstream of 
the shRNA, lhRNA or e-shRNA into the pBluescript II KS plasmid. 
The third-generation, replication-defective, SIN lentiviral vector pLentiLox3.7 
(pLL3.7) was previously described by Rubinson et al. (2003) (Figure 6.1A). This 
vector contains a hybrid 5’ LTR in which the U3 region is replaced with the 
cytomegalovirus (CMV) promoter and enhancer sequence, the packaging signal 
(Ψ), the RRE sequence, the flap sequence or central polypurine tract (cPPT), the 
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central termination sequence (CTS), the enhanced green fluorescent protein 
(EGFP) reporter gene driven by an internal CMV promoter, the woodchuck post-
transcriptional regulatory element (WPRE) and the 3’ LTR in which the cis 
regulatory sequences are completely removed from the U3 region. pLL3.7 
backbone contains as well a murine U6 promoter between XbaI-XhoI sites. This 
vector is thereafter referred to as the empty vector.  
To construct lentiviral vectors expressing one single hairpin molecule, the 
shRNA, lhRNA or e-shRNA transcriptional unit was subcloned into pLL3.7 
between the XbaI and XhoI sites, in place of the murine U6 promoter.  
Lentiviral vectors expressing three hairpin molecules were constructed starting 
from the pBluescript II KS plasmids containing one single hairpin cassette. 
Initially, the plasmid encoding the first cassette was ClaI digested and protruding 
ends were filled-in by the Klenow fragment of DNA polymerase. The linearized 
plasmid was then SalI digested in order to allow the subsequent ligation to the 
second cassette, that was contained on a SmaI-SalI fragment derived from a 
different pBluescript II KS plasmid. The obtained plasmid, encoding two out of 
the three hairpin cassettes, was linearized by SalI digestion and cut with XhoI, 
after treatment with the Klenow enzyme. Next, the third cassette was inserted with 
the XhoI-SmaI restriction sites. Finally, the fragment containing the triple cassette 
was excised with XbaI-XhoI and inserted into the pLL3.7 backbone.  
The resulting plasmids were confirmed by restriction enzyme digestion and DNA 
sequencing. 
 
6.2 Cell cultures 
 
Human embryonic kidney 293T cells were grown in Dulbecco’s modified Eagle’s 
medium (DMEM) (Invitrogen) supplemented with 10% heat-inactivated fetal 
bovine serum (FBS) (Invitrogen). 
The canine thymocyte line stably expressing the human CD4 and CCR5 receptors 
(Cf2Th CCR5+/CD4+) was propagated in DMEM supplemented with 10% FBS, 
G418 (0.5 mg/ml) (Gibco) and Zeocin (0.3 mg/ml) (Invitrogen).  
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Jurkat cells (Clone E6-1) and C8166 cells were maintained in Roswell Park 
Memorial Institute’s 1640 medium (RPMI) (Invitrogen) supplemented with 10% 
FBS.  
Human primary monocyte-derived macrophages (MDMs) were obtained from 
buffy coats of healthy blood donors by Ficoll-Paque PLUS (GE Healthcare) 
purification, followed by plastic adherence of human peripheral blood 
mononuclear cells (PBMCs) for 1 h in RPMI 10% FBS. Non-adherent cells were 
removed and adherent cells were washed with PBS and cultured in RPMI 
containing 10% FBS and macrophage colony-stimulating factor (M-CSF) (500 
U/ml) (Miltenyi Biotec) for 7 days to differentiate into macrophages. Preparation 
purity was evaluated by measuring the percentage of CD14-positive cells through 
FACS analysis, as described below (6.10). The cut-off employed to accept the 
purity of MDM preparation was a CD14-positive percentage higher than 90%.  
Human primary CD4+ T lymphocytes were isolated from 1:2 diluted buffy coats 
by Rosette Sep (StemCell Technologies), according to the manufacturer’s 
instructions. This method is based on negative selection of CD4+ T cells, to 
isolate untouched cells without the risk of activating or damaging them. Briefly, 
an antibody cocktail was directly added to the blood sample to cross-link 
unwanted cells to red blood cells. The antibody complexes were, then, separated 
from the remaining cells by gradient centrifugation, using Ficoll-Paque PLUS. 
The purity of the CD4+ T cell population ranged from 95 to 100%, as estimated 
by FACS analysis using monoclonal antibodies against the human CD4, CD8, 
CD14 and CD19 antigens (6.10). CD4+ T lymphocytes were cultured in RPMI 
medium supplemented with 10% FBS, penicillin (100 U/ml), streptomycin (100 
µg/ml) and phytohemagglutinin (PHA) (5%) (EuroClone). Two days later, PHA 
was removed and cells were used for vector transduction, before IL-2 stimulation 
(6.6). In order to compare yield and purity of different CD4+ T lymphocytes 
purification protocols, the T Cell Isolation Kit II (Miltenyi Biotec) was used for 
the negative selection of CD4+ T cells from PBMCs. To this end, PBMCs were 
obtained from buffy coats after Ficoll-Paque PLUS purification and CD4+ T 
lymphocytes were isolated according to the manufacturer’s instructions. The 
purity of the CD4+ T cell population was assessed by FACS analysis (6.10). 
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6.3 Luciferase assay 
 
The psiCheck2 reporter plasmids were prepared by directed insertion of the RNAi 
target sequence into the XhoI-NotI sites of the psiCheck2 plasmid (Promega), such 
that the target sequence was within the 3’ UTR of the Renilla luciferase gene. To 
obtain RNAi target sequence, two complementary DNA oligonucleotides flanked 
by XhoI and NotI sites were annealed. Sequences of the forward oligonucleotide 
are indicated as follows: shCCR5 target 5’-
CAAGAGGCTCCCGAGCGAGCAAGCTCAGTTTACACCCGATCCACTGGG
GAGCA-3’ (GenBank:X91492.1); shvif target 5’-
CCCTCATCCAAGAATAAGTTCAGAAGTACACATCCCACTAGGGGATGC
TAGATTG-3’ (B.FR.83.HXB2); lhtat/rev target 5’-
GCGGAGACAGCGACGAAGAGCTCATCAGAACAGTCAGACTCATCAAG
CTTCTC-3’ (B.FR.83.HXB2); e-shRNA-derived sitat/rev target 5’-
CCTTAGGCATCTCCTATGGCAGGAAGAAGCGGAGACAGCGACGAAGA
GCT-3’(B.FR.83.HXB2). The RNAi target sequence is underlined. 
For the luciferase assays, 293T cells were plated 1 day before transfection in 96-
well plates at a density of 1x104 cells/well in 100 µl of DMEM 10% FBS. Cells 
were co-transfected with 50 ng of the psiCheck2-derived plasmid and 300 ng of 
the siRNA-expressing vector, using Lipofectamine 2000 reagent (Invitrogen) (0.5 
μl in DMEM serum free to a total volume of 50 μl/well). When three different 
psiCheck2 reporter plasmids were simultaneously tested, 50 ng of each plasmid 
were used for the transfection. Cells were assayed for luciferase expression with 
the Dual Glo Luciferase Assay System (Promega) 48 h post-transfection, 
according to the manufacturer’s instructions, using a Centro LB 960 luminometer 
(Berthold Technologies). Renilla luciferase expression was divided by 
background firefly luciferase expression. Average expression ratios for the control 
vector encoding the scrambled sequence was set to 100% and relative expression 
levels for the other samples calculated accordingly. Three independent 
experiments in triplicate were performed and the data are expressed as the mean ± 
standard deviation. 
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6.4 Lentiviral vector production 
 
Recombinant lentiviral vectors were produced by calcium phosphate transfection 
of 293T cells. Briefly, 2.5×106 cells were seeded on 10 cm Petri dishes and, when 
subconfluent, they were co-transfected with 15 µg of the appropriate gene transfer 
vector, 5 µg of the pMDL plasmid (Dull et al., 1998), 3 µg of the pCMV-Rev 
plasmid and 1,5 µg of the pCMV-G plasmid (Li et al., 2003) (Figure 6.1). The 
culture medium was changed 6 h later. When necessary, the next day DMEM 
10% FBS medium was replaced with RPMI 10% FBS. The culture supernatants 
were collected 48 h after transfection, passed through a 0.45-μm-pore-size filter 
(Millipore) and stored at -80°C until use. When required, the supernatants were 
concentrated by ultracentrifugation. The viral titer was measured by the reverse 
transcriptase activity assay (6.5) and the infectious titer was determined in 293T 
cells by transducing with serial dilutions of the lentiviral stocks in 6-well plates. 
After 72 h, the percentage of EGFP+ cells was determined by flow cytometry 
(6.10). Viral titers typically ranged from 5x107 to 5x108 transducing units (TU)/ml 
for the non-concentrated lentivector stocks and from 5x108 to 2x109 TU/ml for the 
concentrated ones. 
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Figure 6.1. The lentiviral vector and the vector production system. (A) The transfer vector 
pLL3.7 contains a hybrid 5' LTR in which the U3 region is replaced by the CMV promoter, the 
packaging signal (Ψ), the RRE sequence, the flap sequence, the CMV-driven EGFP gene flanked 
by loxP sites, the WPRE sequence and the 3' LTR in which the cis-regulatory sequences have been 
completely removed from the U3 region. The gene(s) of interest (along with a human Pol III 
promoter) can be inserted upstream of the LoxP site which precedes the CMV-EGFP cassette in 
the vector. (B) pMDL contains the gag and pol genes and the RRE sequence from HIV-1 under the 
control of the CMV promoter. (C) pCMV-Rev contains the coding sequence of Rev driven by the 
CMV promoter. (D) pCMV-G contains the VSV-G protein gene under the control of the CMV 
promoter. pA indicates the polyadenylation signal from the human globin gene.  
 
6.5 Reverse transcriptase (RT) activity assay 
 
The RT activity was measured as previously described (Rho et al., 1981). Briefly, 
viral particles were precipitated from 500 µl of the filtered culture supernatants by 
centrifugation at 13000 rpm for 2 h at 4°C. The precipitate was resuspended in 10 
µl of a buffer containing 50 mM Tris-HCl pH 7.5, 1mM dithiothreitol (DTT), 
20% glycerol, 250 mM KCl and 0.25% Triton X-100, transferred in dry ice and 
lysed through three cycles of freezing and thawing. The sample was added to a 
reaction mixture containing 50 mM Tris-HCl pH 7.5, 7.5 mM MgCl2, 0.05% 
Triton X-100, 5 mM DTT, 100 µg/ml polyA, 10 µg/ml oligo-dT and 74 KBq of 
3H-dTTP (2.934 TBq/mmol) in a final volume of 50 µl. The reaction was 
incubated for 1 h at 37°C and transferred on Whatman filters. Filters were 
immediately washed three times in SSC 2X (0.3 M NaCl, 0.03 M sodium citrate 
pH 7.2) for 10 minutes each, twice in absolute ethanol for 10 seconds each and, 
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then, dried. The radioactivity was measured by using a scintillator (Rackbeta 1214 
Wallac) and expressed in counts per minute (cpm). 
 
6.6 Transduction of target cells 
 
For transduction of 293T cells, 2.5x105 cells were seeded per well in 6-well plates 
in 2 ml of DMEM 10% FBS. The next day, medium was replaced with 1 ml of 
medium containing equivalent amounts of vector particles (300000 cpm) and 
polybrene (8 μg/ml). Fresh culture medium was added to the cells approximately 
8 h later. Two to three days after transduction, cells were detached from the tissue 
culture, with one aliquot used for FACS analysis of EGFP+ cells (6.10) and the 
remaining aliquots replated into 6-well plates at 2.5x105 cells/well either for 
recombinant HIV-1 challenge (6.7) or Gag expression analysis (6.9). 
Cf2Th CCR5+/CD4+ cells were plated at 2x105 cells/well in 6-well plates, 
cultured overnight and transduced with lentiviral vectors at an m.o.i. of 50 TU/cell 
in 1 ml of DMEM 10% FBS without antibiotics, in the presence of polybrene (8 
μg/ml). Approximately 8 h later, medium was removed and replaced with 2 ml of 
fresh DMEM 10% FBS containing G418 and Zeocin. Three days after 
transduction, the Cf2Th CCR5+/CD4+ target cells were detached from the culture 
plate by treatment with PBS and 5 mM EDTA. The cell suspension was diluted in 
medium and stained with monoclonal antibody to human CCR5 for FACS 
analysis (6.10). 
Transduction of MDMs was performed over two consecutive days by incubating 
1x106 cells with vectors (from 1x107 to 1x108 TU in different experiments) in 1 
ml of RPMI 10% FBS. After transduction, macrophages were maintained in 
culture medium supplemented with M-CSF (500 U/ml) for 72 h, before FACS 
analysis of CCR5 cell surface expression (6.10).  
For transduction of Jurkat cells, 1x106 cells were incubated with vectors at an 
m.o.i. of 50-100 TU/cell, in a total volume of 1 ml. After three days of culture, the 
transduction efficiency was ascertained by FACS analysis on the basis of EGFP 
expression (6.10) and cells were used for HIV-1 infection (6.7). 
CD4+ T lymphocytes (1x106 cells) were incubated with the lentiviral vectors at an 
m.o.i. of 50 TU/cell in the presence of 8 µg/ml polybrene and spin-infected at 
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1200 rpm for 2 h at 25°C. After spin-inoculation, fresh RPMI 10% FBS medium 
containing IL-2 (100 U/ml) (R&D Systems), penicillin (100 U/ml) and 
streptomycin (100 µg/ml) was added to the cells. GFP, CD4 and CCR5 expression 
was analyzed by FACS at multiple time points after transduction (6.10). Of note, 
although an m.o.i. of 50 was used for transduction with different vectors, actual 
transduction efficiency appeared to vary from sample to sample, depending on the 
initial titers of the vector preparations. At day 4 after CD4+ T lymphocytes 
transduction, homogeneous EGFP+ populations were obtained by flow cytometric 
sorting and used for HIV-1 infection (6.7). 
 
6.7 Wild-type and recombinant HIV-1 stock production and infection 
 
HIV-1 HXBc2 Vpr+ Vpu+ Nef+ was generated by transfection of 5x106 Jurkat 
cells with 10 µg of the pSVC Vpr+ Vpu+ Nef+ construct by the DEAE-dextran 
technique. This plasmid is a derivative of the pSVC21, containing the HIV-1 
HXBc2 molecular clone (Ratner et al., 1985), where the vpr, vpu and nef 
sequences were substituted with those derived from the pNL4-3 (vpr/vpu) (Adachi 
et al., 1986) and pLAI (nef) (Peden et al., 1991) molecular clones, in order to 
introduce functional vpr, vpu and nef genes. Jurkat cell supernatants were 
harvested at approximately 48 h post-trasfection and filtered (pore size, 0.45 µm). 
Viral titer was determined as TCDI50 (50% tissue culture infectious dose)/ml on 
C8166 cells using the Reed and Muench method (Jawetz et al., 1980), as well as 
by measuring the RT activity (6.5). 
HIV-1 NL4-3-ADA stocks were produced by calcium phosphate transfection with 
15 µg of the infectious proviral plasmid (gift from H. Göttlinger, University of 
Massachusetts Medical School) in 293T cells, as described above (6.4). pNL4-3-
ADA plasmid is a derivative of the pNL4-3, containing the HIV-1 NL4-3 
molecular clone, where the env sequence was replaced with that derived from the 
CCR5-tropic ADA strain (Theodore et al., 1996). RT assay was performed in 
order to determine viral titer (6.5). 
Four days after vector transduction (6.6), 1x106 Jurkat cells were infected with 
HXBc2 Vpr+ Vpu+ Nef+ at an m.o.i. of 0.1 infectious units (IU)/cell for 1 h at 
37°C, in a total volume of 300 µl. After the incubation, the cells were washed 
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three times with PBS, seeded in 12-well plates at a density of 1x106 cells/ml and 
cultured in RPMI 10% FBS medium. The culture supernatants were collected at 
different days post-infection and the RT activity was measured (6.5).  
For CD4+ T lymphocytes infection, 1x106 activated EGFP+ (6.6) or control cells 
(untransduced CD4+ T cells) were challenged with equivalent reverse 
transcriptase units (10000 cpm) of either HXBc2 Vpr+ Vpu+ Nef+ or NL4-3-
ADA at 24 h after cell sorting. Infection was carried out as previously described 
and cells were plated with RPMI 10% FBS supplemented with penicillin (100 
U/ml), streptomycin (100 g/ml) and IL-2 (100 U/ml). The RT activity in culture 
supernatants was monitored at different time points after infection (6.5). 
Recombinant HIV-1 virus to be used for 293T infection was produced by co-
transfection of 293T cells with 5 µg of pHXBΔenvCAT and 3 µg of pCMV-G, by 
the calcium phosphate method (6.4). The pHXBΔenvCAT plasmid contains the 
HXBc2 HIV-1 provirus with a 580 bp deletion in the env gene and the 
chloramphenicol acetyltransferase (CAT) gene replacing the nef gene (Terwilliger 
et al., 1989; Helseth et al., 1990). All the recombinant HIV-1 viruses were 
quantified by RT assay (6.5). 
Transduced 293T cells (6.6) were infected by incubation with the recombinant 
virus (10000 cpm) in 1 ml of medium. After overnight incubation at 37°C, fresh 
medium was added to the cells and, two days later, they were lysed and used for 
determination of CAT activity (6.8). 
 
6.8 Chloramphenicol acetyltransferase (CAT) activity assay 
 
For CAT activity assays, cells were lysed in 150 µl of 250 mM Tris-HCl pH 7.5 
and protein concentration in the lysates was determined with the BCA Protein 
Assay Kit (Thermo Scientific) using BSA as a standard, according to the 
manufacturer’s instructions. Equivalent amounts of proteins were used for 
determination of CAT activity, as previously described (Sodroski et al., 1984). 
The different forms of acetylated chloramphenicol were separated by thin layer 
chromatography (TLC) and visualized with an autoradiografic exposure of 12 h 
(Kodak Biomax films). The quantitative evaluation was obtained by cutting the 
TLC paper at the level of the corresponding spots, and by performing a 
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quantification of the spots at the scintillator. The percentage of conversion in the 
acetylated forms was calculated as follows: % of conversion = (mono- + di-
acetylated forms)/(non acetylated + mono-. + di-acetylated forms). Calculated 
with the above formula, the percentage of conversion is linear for values up to 
50%. 
 
6.9 Gag expression analysis 
 
Transduced 293T cells (6.6) or control cells were transfected by the calcium 
phosphate technique with pCMV-Rev, pMDL, or with both plasmids (6.4; Figure 
6.1B-C). At 24 h cells were harvested, washed with PBS and lysed in 
radioimmunoprecipitation assay (RIPA) buffer [140 mM NaCl, 8mM Na2HPO4, 2 
mM NaH2PO4, 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.05% sodium 
dodecyl sulphate (SDS)]. For immunoblot analysis, proteins were resolved by 
SDS-polyacrylamide gel electrophoresis (PAGE) and electroblotted onto a Protran 
membrane (Whatman). The membranes were incubated with the appropriate 
primary antibody, namely a rabbit polyclonal anti-HIV-1 capsid antiserum (anti-
HIV-1 p24 Gag antiserum; ABi Advanced Biotechnologies) or a mouse anti-α-
tubulin antibody (Monoclonal Anti-α-Tubulin antibody, Sigma). Blots were 
visualized with a peroxidase-conjugated anti-rabbit or anti-mouse IgG secondary 
antibody (GE Healthcare) and developed with enhanced chemiluminescence 
reagents (GE Healthcare), as described elsewhere (Strack et al., 2000). 
 
6.10 FACS analysis 
 
Cells (typically 5x105) were stained with monoclonal antibodies to human CCR5 
(APC Mouse Anti-Human CD195, BD Pharmingen), CD4 (PE-Cy7 Mouse Anti-
Human CD4, BD Pharmingen), CD14 (CD14-PE, human, Miltenyi Biotec), CD8 
(Anti-Human CD8a APC, eBioscience) or CD19 (CD19-FITC, human, Miltenyi 
Biotec), according to the manufacturer’s instructions. The cells were also stained 
with isotype controls for each of the specific antibodies, as well as with the 7-
Amino-Actinomycin D (7-AAD) viability dye (BD Pharmingen). When 
necessary, cells were either incubated with FcR blocking reagent (Miltenyi 
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Biotec) before staining or fixed with 2% formaldehyde before acquisition on the 
flow cytometer. Samples were acquired on either a LSRII or FACSCalibur 
(Becton Dickinson) and the data analysis was performed with FlowJo (Tree Star) 
or CellQuest (Becton Dickinson) software, respectively. 
 
6.11 MTT cell viability assay 
 
293T cells were seeded at a density of 1x104 cells/well in 100 μl of DMEM 10% 
FBS in 96-well plates and grown one day before the transfection with lentiviral 
vectors (300 ng), using Lipofectamine 2000 reagent, as previously described (6.3). 
At 48 h post-transfection, MTT (Roche) was added according to the 
manufacturer’s instructions.  
Jurkat cells and CD4+ T lymphocytes were plated in 96-well plates at a density of 
105 cells/well in 100 μl of RPMI 10% FBS, 72 h post-transduction (6.6). After 
overnight recovery, MTT assay was performed.  
Optical density was measured at 620 nm and the value obtained for control cells 
(untransfected/untransduced cells) was set to 100%. Relative cell viability for 
other samples was calculated accordingly. Three independent experiments in 
triplicate were performed and the data are expressed as the mean ± standard 
deviation. 
 
6.12 Cloning and analysis of lentiviral vector insertion sites 
 
Vector integration sites were determined by linker-mediated polymerase chain 
reaction (LM-PCR) followed by Sanger sequencing of amplicons, as previously 
described (Cattoglio et al., 2007). Briefly, genomic DNA was extracted from 0.5 
to 5x106 transduced CD4+ T lymphocytes (6.6), digested with MseI and ligated to 
a TA-protruding linker, obtained by annealing the following oligonucleotides: 5’-
GTAATACGACTCACTATAGGGCTCCGCTTAAGGGAC-3’ and 5’-
TAGTCCCTTAAGCGGAG-3’. The genomic DNA was further digested with 
SacI/NarI, in order to prevent amplification of internal vector sequences. Next, 
LM-PCR was performed with primers annealing to the vector 3′ LTR and the 
linker (3’ LTR primer: 5′-AGTGCTTCAAGTAGTGTGTGCC-3′; linker primer: 
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5’-GTAATACGACTCACTATAGGGC-3’; 3’ LTR nested primer: 5′-
CGTATCGCCTCCCTCGCGCCATCAGCGTAGTCTGTTGTGTGACTCTGGT
AAC-3′; linker nested primer: 5’-
CTATGCGCCTTGCCAGCCCGCTCAGAGGGCTCCGCTTAAGGGAC-3’). 
LM-PCR libraries were subjected to gel-size selection in a range of 250-700 bp. 
Amplicons were gel-purified (Gel-Extraction Kit, Qiagen) and shotgun-cloned 
(TOPO TA Cloning Kit, Invitrogen) into DH5α E.coli cells. Finally, LM-PCR 
amplicons were Sanger-sequenced, generating a collection of vector-human 
genome junction reads.  
Valid reads consisted of the following sequences: the 3’ LTR nested primer, the 
last part of the vector LTR up to a CA dinucleotide, the adjacent human genome 
up to the first MseI site and the linker nested primer. Human genome sequences 
longer than 20 bp were mapped onto the hg19 release of the human genome by 
the University of California Santa Cruz (UCSC) BLAT alignment tool 
(http://genome.ucsc.edu) and not univocally mapping sequences were discarted. 
The genomic coordinates of the first nucleotide following the LTR were 
considered as the vector integration site (IS). Only sequences featuring a unique 
best hit with at least 95% of identity to the human genome were taken into 
account to annotate bona fide ISs. 
ISs were classified as inside or outside genes when occurring within or outside a 
gene-body region (RefSeq genes collection, hg19 release). Exon or intron 
localization of ISs were determined by manually-curated inspection on the UCSC 
Genome Browser tool (http://genome.ucsc.edu). 
Functional annotation of ISs targeted genes was performed by the DAVID 6.7 
Functional Annotation tool (http://david.abcc.ncifcrf.gov). Functional categories 
are derived from the Gene Ontology (GO)-Biological Process classification. 
Statistical significance of any given category with respect to the human genome, 
used as background population, was set at a p-value < 0.05. 
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7. RESULTS 
 
7.1 Selection of anti-HIV-1 shRNAs and development of lentiviral vectors 
expressing the specific shRNAs as single transcriptional units 
 
To inhibit HIV-1 infection at multiple stages of the virus life cycle, an original 
combination of three RNAi agents, which individually confer resistance to viral 
infection, was tested. Their targets include the transcripts of the CCR5 cellular 
gene and those of the vif and the tat/rev viral genes. 
CCR5 is mainly expressed on the surface of CD4+ T lymphocytes and 
monocyte/macrophages and it is used by most HIV-1 strains as a co-receptor to 
enter target cells. Several evidences make CCR5 an intriguing target for HIV-1 
therapy. Firstly, individuals homozygous for the truncated ∆32 variant of the 
CCR5 gene are resistant to HIV-1 infection and are otherwise healthy (Samson et 
al., 1996). Secondly, targeting of cellular co-factors that are essential for HIV-1 
replication represents a promising anti-escape approach, since the mutation rate of 
the cellular DNA replication machinery is significantly lower than that of the 
lentiviral reverse transcriptase enzyme. Thus, the chance that resistance mutations 
are selected in host mRNAs is negligible compared to HIV-1 target sequences 
(Knoepfel et al., 2012). Thirdly, anti-HIV-1 genes which block pre-integration 
steps of HIV-1 infection will prevent the generation of provirus and viral 
reservoirs, that are the main reasons for the failure to cure HIV-infected 
individuals (Walker et al., 2012). Taken together, these considerations prompted 
us to select a shRNA targeting CCR5 (shCCR5), that has been previously 
described by Chen and co-workers (Liang et al., 2010). This molecule has been 
shown to have antiviral potency both in HSCs and in non-human primates, in the 
absence of cytotoxicity (Liang et al., 2010; An et al., 2007). 
Vif is a viral accessory protein that enhances virus infectivity and is essential for 
viral replication and pathogenesis in vivo. Vif counteracts the restriction factors of 
the cellular APOBEC3 cytosine deaminases family (i.e. APOBEC3G and 
APOBEC3F) by inducing their proteasomal degradation. In the absence of Vif 
expression, the APOBEC3 proteins are incorporated into the newly synthesized 
virus particles, leading to the hypermutation in the viral DNA during reverse 
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transcription in the next round of infection (Mangeat et al., 2003). In addition, it 
has been demonstrated that APOBEC3G also induces defects in reverse 
transcription and DNA integration (Bishop et al., 2008; Mbisa et al., 2007). We 
selected a shRNA targeting a highly conserved sequence within the vif open 
reading frame (shvif) (Lee et al., 2005), that has been proven to be effective 
against viruses from multiple clades, including primary viral isolates from clades 
A, B, C, D and E. 
Tat and Rev are regulatory viral gene products, essential for viral gene expression. 
The former transactivates transcription from the HIV-1 LTR by binding to the 
TAR element at the 5’ end of all viral mRNAs, while the latter promotes the 
export of unspliced or singly spliced viral mRNAs from the nucleus by binding to 
the RRE sequence (Feng and Holland, 1988; Malim et al., 1989). Interestingly, 
the tat and rev first exons overlap, allowing to interfere with both gene transcripts 
by means of a single siRNA. To inhibit Tat and Rev expression, we selected a 
long hairpin RNA (lhRNA) generating two distinct siRNAs against contiguous 
sequences in the tat/rev common transcript (lhtat/rev) (Sano et al., 2008). In this 
context, mutants that arise should have a selective disadvantage because the 
reading frames for the Tat and Rev proteins are different. Therefore, silent third-
position codon changes for one gene will very often result in an amino acid 
alteration for the other gene, thereby affecting expression of that gene. G:U 
wobble parings were included in the sense strand of the lhtat/rev, to attenuate the 
innate immune response to long dsRNAs. 
In general, the shRNA/lhRNA design was based on the prototype shRNA hairpin 
transcript published by Brummelkamp and coworkers in 2002: complementary 
sense and antisense strands, a 9-nucleotide hairpin loop and 3’-UU overhang 
(Brummelkamp et al., 2002). The antisense strand of this shRNA design, upon 
Dicer processing, will form the guide strand that instructs RISC for antiviral 
attack. The complete shRNA/lhRNA cassette consists of a human RNA 
polymerase III promoter and the shRNA/lhRNA sequence followed by the 
TTTTT termination signal (Figure 7.1A-B). The selected promoters included the 
human U6 small nuclear RNA promoter (U6) and the human RNase P RNA H1 
promoter (H1), which represent the two most commonly used promoters to drive 
shRNA expression. In addition, the 7SK small nuclear RNA promoter (7SK) was 
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further adopted, to better characterize its activity when used to express RNAi 
triggers. Promoters were either amplified from human genomic DNA or obtained 
as a restriction fragment from the appropriate plasmid. shCCR5 and shvif were 
constructed as synthetic DNA, while the lhtat/rev was generated by a two-step 
PCR approach, as described in details in the Material and Methods section (6.1). 
Initially, the single shRNA/lhRNA cassette was cloned in a prototypical 3rd 
generation SIN lentiviral vector (Rubinson et al., 2003). As indicated in Figure 
7.1C, a total of nine different vectors encoding the shRNA cassette in the forward 
orientation were constructed, to define the best combination of promoter-RNAi 
effector. An additional vector expressing the H1-driven lhtat/rev unit in the 
antisense orientation was obtained during the cloning steps, and turned out to be 
useful in order to assess the influence of promoter orientation on siRNA efficacy. 
Moreover, three scrambled vectors to be used as controls were developed. Each of 
these expresses a shRNA, under the control of either the U6, the 7SK or the H1 
promoter, generating an siRNA that is three nucleotides different from the one 
produced by the shCCR5. All the vectors harbor the CMV-driven EGFP reporter 
gene, as a marker for tracking transduced cells. 
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Figure 7.1. Schematic diagram of the single shRNA-expressing vectors. (A) Schematic 
illustration of a Pol III promoter-driven shRNA or lhRNA transcriptional unit. A sequence of 2 U 
nucleotides that are derived from the transcription termination signal is shown. The intended 
mechanism of transcription and processing of the hairpin molecule to form one or multiple 
siRNAs is illustrated. (B) Sequence and predicted structure of the shRNAs and lhRNA. The guide 
strand is marked in red, while G:U pairings are indicated with an arrowhead. (C) A self-
inactivating third generation lentiviral vector, pLL3.7, was utilized to derive the anti-HIV-1 
constructs. The single shRNA or lhRNA along with its independent Pol III promoter is inserted 
upstream of the LoxP site, which precedes the EGFP transcriptional unit. Arrows indicate the 
transcriptional orientation of the RNAi trigger cassette.  
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7.2 Activity of the single shRNA vectors by means of the luciferase 
knockdown assay 
 
Initially, to evaluate the silencing activity of the single shRNA-expressing vectors, 
293T cells were co-transfected with each vector along with a reporter plasmid 
encoding the renilla luciferase gene fused with the respective RNAi target 
sequence. In addition, the reporter plasmid encodes the firefly luciferase gene to 
control for transfection efficiency (psiCheck2-CCR5, psiCheck2-vif, psiCheck2-
tat/rev) (Figure 7.2A). Renilla and firefly luciferase expression was measured 2 
days after transfection and the ratio was used to calculate the relative luciferase 
activity. The renilla/firefly ratio in the presence of the scrambled vectors was set 
at 100%. 
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Figure 7.2. Knockdown of luciferase reporter by the single shRNA-expressing vectors. (A) 
psiCheck2-derived vectors that include the indicated RNAi target sequences inserted downstream 
of the renilla luciferase ORF. The control firefly luciferase cassette, present on the same plasmid, 
is also shown. Renilla and firefly luciferase genes are under the control of the simian virus 40 
(SV40) and the herpes simplex virus thymidine kinase (HSV TK) promoter, respectively. (B-D) 
Average normalized ratios of the renilla:firefly luciferase activity when cells were transfected with 
the psiCheck2-CCR5, psiCheck2-vif or psiCheck2-tat/rev reporter plasmid along with the vectors 
expressing, respectively, the shCCR5 (B), shvif (C) or sense/antisense lhtat/rev (D), under the 
control of the indicated promoters. The scrambled hairpin has been included as a control (C-). The 
average values from three independent experiments, with standard deviations, are given (*, p-value 
< 0.05; **, p-value < 0.01; ***, p-value < 0.001; t-test, relative to C-). 
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When testing the shCCR5 vectors, highly effective knockdown of the renilla 
luciferase expression was achieved, with the U6 and the H1 promoters mediating 
an almost complete suppression of the reporter gene activity (Figure 7.2B). When 
the vif sequence was inserted downstream of the renilla luciferase gene, the shvif 
vectors mediated a less pronounced silencing activity. Indeed, only the H1-driven 
shvif was capable of 40% inhibition of reporter gene expression (Figure 7.2C). On 
the contrary, the lhtat/rev expression cassette diminished renilla luciferase activity 
by approximately 70-90%. In this context, the H1 promoter turned out to be the 
most efficient regardless of the cassette orientation (Figure 7.2D). 
Taken together, these results indicated that siRNA activity is influenced by the 
used promoter, while promoter orientation does not appear to have a major impact 
on silencing efficacy. Thus, only vectors harboring the shRNA cassette in the 
forward orientation were used for subsequent experiments. 
 
7.3 The shCCR5 downregulates CCR5 expression in cell cultures 
 
To examine the activity of the shCCR5 in targeting the full length CCR5 
transcript, the suppression of CCR5 cell surface expression was tested in canine 
Cf2Th thymocytes stably expressing the human CD4 and CCR5 molecules 
(Cf2Th CD4+/CCR5+) (LaBonte et al., 2003). To this end, cells were transduced 
with vectors encoding either the shCCR5 or the scrambled hairpin at an m.o.i. of 
50 TU/cell and, 72 h post-transduction, samples were analyzed by FACS for cell 
surface CCR5 expression. The results of a representative experiment performed 
with the H1-driven shCCR5 vector are reported in Figure 7.3. 
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Figure 7.3. Reduction of CCR5 surface expression on CCR5+ Cf2Th canine thymocytes 
transduced with the shCCR5 vectors. Canine thymocytes expressing human CD4 and CCR5 
were transduced with either the shCCR5-expressing vectors or the scrambled counterparts. The 
cells were harvested 3 days after transduction and analyzed by FACS with anti-human CCR5 or 
isotype control antibody staining. (A) CCR5 surface expression on control cells (C-). The results 
are exhibited as CCR5 vs forward scatter (FSC) dotplots with cell populations in the live canine 
thymocytes gate (typically > 90%). (B) FACS histogram showing the mean fluorescence intensity 
(MFI) for CCR5 in cells transduced with either the H1-shCCR5 vector (red curve) or the 
respective scrambled control (blue curve). The graph is referred to productively transduced cells, 
gated on the basis of their EGFP signal (EGFP+ cells). 
 
Among the productively transduced thymocytes, i.e. 80% and 73% of EGFP+ 
cells for the shCCR5 vector and the scrambled vector, respectively (data not 
shown), CCR5 expression in shCCR5 population dropped to 35% with respect to 
the level of the scrambled-transduced cells (Figure 7.3B). Importantly, this result 
was observed despite the very high amount of CCR5 expressed on thymocytes 
surface, as compared to the physiological expression level on human primary 
macrophages. 
To further investigate the activity of the shCCR5 in physiologically relevant cells, 
the suppression of CCR5 cell surface expression was assessed in human primary 
macrophages, which are the natural target of HIV-1 infection. As a first step, 
monocytes were purified from buffy coats of healthy blood donors by Ficoll-
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Hystopaque gradient and cells were cultured in the presence of M-CSF to induce 
macrophage differentiation. The preparation purity was evaluated by measuring 
the percentage of CD14-positive cells through FACS analysis, considering a cut-
off value higher than 90%. Next, transduction of monocyte-derived macrophages 
(MDMs) with vectors expressing the shCCR5 was performed over 2 consecutive 
days. As a control, macrophages were transduced with the scrambled vectors. 
CCR5 and EGFP expression level was assessed by FACS at approximately 72 
hours after the second transduction. Transduction efficiency typically ranged from 
20% to 60%, based on EGFP expression. Figure 7.4 shows FACS plots and 
trsnduction efficiency from two representative donors (1 and 2). 
 
  
 
 
Vector 
EGFP+ cells (%) 
Donor 1 Donor 2 
U6shCCR5 47 26 
U6scrambled 44 33 
7SKshCCR5 39 28 
7SKscrambled 28 29 
H1shCCR5 23 33 
H1scrambled 42 63 
Donor 1
Donor 2
FSC
C
D
14
isotype control anti-CD14 AbA 
Table 1 
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Figure 7.4. Reduction of CCR5 surface expression on human primary macrophages 
transduced with the shCCR5 vectors. (A) Monocytes derived from PBMCs were cultured in the 
presence of M-CSF for 7 days to differentiate to macrophages. MDM preparation purity was 
assessed by FACS analysis for CD14 expression on cell surface. (B) MDMs were transduced with 
vectors expressing the shCCR5 or the scrambled hairpin over 2 consecutive days. Cells were 
harvested 3 days after the second transduction and stained with anti-human CCR5 antibody. The 
expression of EGFP (Table 1) and CCR5 was analyzed by flow cytometry. Results from two 
donors are shown (1 and 2). The panel displays CCR5 vs FSC dotplots with cell populations in the 
live macrophage gate (typically > 40%). The quadrant lines were defined by isotype control 
staining. 
 
As shown in Figure 7.4B (Donor 1) ≅ 90% of the control cells were CCR5+. A 
marked downregulation of CCR5 expression was observed when cells were 
transduced with the shCCR5 vectors in comparison with the respective scrambled 
controls. Specifically, the U6- and the H1-driven shCCR5 resulted in the most 
striking CCR5 reduction, according to the results obtained with the luciferase 
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assay (7.2). These data were confirmed with donor 2-derived macrophages. Of 
note, in this latter case an overall less pronounced CCR5 dowregulation by the 
shCCR5 was detected, suggesting a certain degree of inter-donor variability 
(Figure 7.4B, Donor 2). 
 
7.4 Effect of the lhtat/rev on HIV-1 gene expression 
 
Taking into account that the lhtat/rev produces two siRNAs, simultaneously 
targeting the HIV-1 tat and the rev genes, we sought to evaluate the anti-Tat and 
the anti-Rev effect independently of each other. With this aim, two different 
experimental setups were designed, as described below. Importantly, although the 
lhtat/rev target sites are also present in the Rev-expressing plasmid used to 
produce vector particles, there were no deleterious consequences on vector titers, 
as they were comparable to those obtained with the shCCR5, shvif and scrambled 
constructs. 
 
7.4.1 Inhibition of Tat-dependent gene expression 
 
In an effort to investigate the effect of targeting the tat viral transcript 
independently of the Rev downregulation, lhtat/rev-transduced 293T cells were 
challenged with an HIV-1 recombinant virus. To this end, a VSV-G-pseudotyped 
HIV-1 encoding the bacterial chloramphenicol acetyltransferase (CAT) gene in 
place of the nef gene was adopted. Since the recombinant virus contains a deletion 
in the env gene, it is capable of only one cycle of replication (Terwilliger et al., 
1989; Helseth et al., 1990). CAT activity was, then, evaluated in the lysates of 
target cells. Indeed, in this context, the CAT gene transcription is Tat-dependent, 
as it is driven by the viral LTR, while the CAT transcript doesn’t require Rev 
function, since it undergoes the same multiple splicing events used for the natural 
HIV-1 nef message. 
293T cells were transduced with equivalent RT units (300000 cpm) of the 
lhtat/rev vectors or the scrambled counterpart. Once determined transduction 
efficiency on the basis of EGFP expression, cells were challenged with the CAT-
reporter virus (10000 cpm) at 48 h post-transduction. Two days later, the 
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efficiency of CAT gene expression was evaluated in the target cells. The results of 
a representative experiment, that was performed two times, are reported in Figure 
7.5. 
 
 
Vector EGFP+ cells (%) 
U6lhtat/rev 32 
U6scrambled 42 
7SKlhtat/rev 42 
7SKscrambled 47 
H1lhtat/rev 47 
H1scrambled 29 
 
 
Figure 7.5. Effect of the lhtat/rev on Tat-dependent gene expression in 293T cells. 293T cells 
were transduced with either the lhtat/rev or the scrambled vectors and EGFP expression was 
analyzed by FACS 3 days post-transduction. The percentage of EGFP+ cells is reported (Table 2). 
Untransduced (C+) and transduced cells were exposed to a VSV-G pseudotyped HIV-1 reporter 
virus, encoding the CAT gene in place of the nef gene. The results of the CAT assay performed on 
the cell lysates two days post-infection are presented. One representative experiment is shown (C-: 
untransduced and uninfected cells). 
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Figure 7.5 highlights that vector-transduced cells exhibited an overall reduction of 
the CAT activity if compared with control cells (p-value < 0.001). However, when 
comparing the lhtat/rev-expressing cells with the respective scrambled 
counterpart, only a slight reduction in the CAT activity was detected. Considering 
that the transduced population that underwent viral challenge consisted of a 
mixture of EGFP-positive and EGFP-negative cells, we hypothesised that the 
effect of the lhtat/rev might have been partially masked by the EGFP-negative 
cells. 
 
7.4.2 Inhibition of Rev-dependent gene expression 
 
To dissect the role of Rev downregulation independently of Tat silencing effects, 
the expression of the HIV-1 gag gene under the control of a Tat-independent 
promoter was analyzed in 293T cells. To this end, lhtat/rev-transduced cells were 
co-transfected with a plasmid harboring the gag gene and the RRE sequence along 
with a plasmid encoding the Rev protein. In the presence of Rev, the gag 
transcript is exported from the nucleus to the cytoplasm, thanks to the binding of 
Rev to the RRE element, where it can be properly translated into the Gag 
precursor protein. On the contrary, in the absence of Rev expression, the gag 
transcript is retained into the nucleus and undergoes degradation. Importantly, as 
both Gag and Rev are expressed from a CMV promoter, it is possible to 
specifically evaluate the effect of lhRNA-mediated Rev downregulation. 
As a first step, it was important to determine the minimum amount of the Rev-
encoding plasmid required to express Gag. Thus, 293T cells were co-transfected 
with increasing amounts of the Rev plasmid along with a fixed amount of the Gag 
plasmid and harvested 24 h later. Proteins derived from the cell lysates were 
analyzed by SDS-PAGE, followed by Western blotting with an anti-HIV-1 Gag 
monoclonal antibody to examine Gag expression. It was found that a tiny amount 
of the Rev plasmid is sufficient to promote Gag expression, as demonstrated by 
the presence of both the Gag precursor protein (Pr55) and the mature capsid 
protein (p24) in cells transfected with as low as 10 ng of the Rev plasmid (Figure 
7.6A).  
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Based on these results, the amount of the Rev plasmid used for transfecting 
lhtat/rev-expressing cells was accordingly decreased. Before transfection, 
transduced cells were FACS analyzed to assess transduction efficiency, that 
ranged from 30% to 50% for a typical experiment (data not shown). Next, 
transfection using only 1 ng of the Rev-expressing plasmid along with the Gag 
construct was carried out at 72 h post-transduction. Twenty-four hours later, cells 
were harvested and Gag expression was analyzed. As indicated in Figure 7.6B, 
the lhtat/rev caused a reduction in p24 protein expression as compared to the 
scrambled controls, regardless of the used promoter.  
 
 
 
Figure 7.6. Effect of the lhtat/rev on Rev-dependent gene expression in 293T cells. (A) The 
HIV-1 Gag- or Rev-expressing constructs were transfected into 293T cells either alone (800 ng 
and 150 ng, respectively) or in combination, by using a fixed amount of the Gag-expressing 
plasmid (400 ng or 800 ng) along with increasing amounts of the Rev-expressing plasmid (10 ng 
to 150 ng), as indicated. At 24 h, the cells were lysed and proteins derived from the cell lysates 
were analyzed by SDS-PAGE, followed by Western blotting with an anti-HIV-1 Gag monoclonal 
antibody (Pr55 and p24) (C-: untransfected cells). (B) 293T cells, either untransduced (NT) or 
transduced with the lhtat/rev or the scrambled vectors, were transfected with the Gag- and Rev-
expressing constructs (1 ng and 400 ng, respectively). As controls, NT cells were transfected with 
the Gag- or Rev-expressing plasmid alone, or neither of them (C-). Cell lysates were analyzed 24 h 
after transfection by SDS-PAGE, followed by Western blotting employing an anti-HIV-1 Gag 
monoclonal antibody (Pr55 and p24) or an anti-α-tubulin monoclonal antibody (Tub), as indicated. 
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7.5 Development of lentiviral vectors expressing a combination of anti-
HIV-1 siRNAs 
 
Similar to current antiviral drugs used in the clinic, the application of a single 
RNAi agent against HIV-1 is not sufficient to maintain inhibition. HIV-1 can 
escape from inhibition by mutating either its RNAi target sequence or a region 
outside the target sequence, that alter the local RNA secondary structure. 
Therefore, a successful RNAi-based therapy against HIV-1 requires the use of 
multiple siRNAs (ter Brake et al., 2006). In this context, the simultaneous 
expression of multiple shRNA transcriptional units represents one of the most 
promising combinatorial strategies.  
Starting from these considerations, we cloned the shCCR5, the shvif and the 
lhtat/rev in a single vector as independent transcriptional units. A number of 
vectors were constructed, differing from each other by either the promoter driving 
the expression of each shRNA or the position of the shRNA cassette (Figure 
7.7A). One vector was obtained by combining each shRNA with the most 
efficient promoter, as resulted with the luciferase knockdown assay (i.e. 
U6shCCR5-H1lhtat/rev-H1shvif) (7.2). As a consequence, the vector contains two 
copies of the H1 promoter. Considering that the presence of repeated regulatory 
sequences has been associated with genetic instability and reduced titer of the 
vector system (Liu et al., 2007; ter Brake et al., 2008), different promoters were 
used for developing the other combinatorial vectors. Specifically, in another 
vector the U6 and the H1 promoters were maintained to express the shCCR5 and 
the lhtat/rev, respectively, which represent the most potent RNAi effectors, while 
the 7SK promoter was used to express the shvif (i.e. U6shCCR5-H1lhtat/rev-
7SKshvif). In another combination, the H1lhtat/rev and the 7SKshvif cassettes 
were swapped, as compared to the above-described vector, in order to assess the 
impact of cassette position on vector antiviral activity (i.e. U6shCCR5-7SKshvif-
H1lhtat/rev). Finally, in another context, the combination of promoter-shRNA was 
designed to optimize the overall silencing effect mediated by the three RNAi 
effectors (i.e. 7SKshCCR5-U6lhtat/rev-H1shvif). 
In addition to the multiple shRNA cassette strategy, the use of extended shRNAs 
(e-shRNAs) has been shown to provide durable anti-HIV-1 inhibition (Liu et al., 
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2009). e-shRNAs can express up to three siRNAs, stacked on top of each other 
along the stem of the hairpin, under the control of a single promoter.  
To compare the efficacy of different combinatorial anti-HIV-1 platforms, we 
designed an e-shRNA encoding three siRNAs targeting the CCR5, the tat/rev and 
the vif transcripts, under the control of the U6, the 7SK or the H1 promoter 
(Figure 7.7B). The siRNAs against the CCR5 and the vif transcripts have the same 
target sequence as compared to the shCCR5 and the shvif, respectively. On the 
contrary, the siRNA against the tat and rev genes has a different target sequence 
with respect to both the siRNAs produced by the lhtat/rev. Indeed, since the stem 
region of the extended hairpin has an upper size limit of 66 bp for effective 
production of multiple and functional siRNAs (Liu et al., 2009), the lhtat/rev 
guide strand sequence was replaced with a shorter one, generating one single 
siRNA that targets a distinct region of the tat/rev common transcript (Liu et al., 
2009). There is some evidence suggesting that Dicer processing of e-shRNAs may 
not be equal across the span of the duplex, favoring the production of the siRNAs 
generated from the hairpin stem base (Saayman et al., 2008; Liu et al., 2009). 
Thus, the potent siCCR5 was positioned as first, close to the stem base, followed 
by the sitat/rev and the sivif, ordered as second and third, respectively. This 
configuration allows the siRNA that blocks the very early stages of HIV-1 
infection to be potentially expressed at higher levels than the ones interfering with 
post-integration steps. A three-nucleotide linker sequence was inserted between 
contiguous siRNAs, as this is the most frequently adopted spacer, even if only few 
studies addressed this point up to date (Liu et al., 2007; Saayman et al., 2008). 
Finally, G:U wobble base pairs were included at regular intervals in the sense 
strand of the e-shRNA, to suppress the innate immune response to dsRNAs and to 
facilitate the propagation of the e-shRNA-encoding plasmids in E.coli (Sano et 
al., 2008; Saayman et al., 2008). 
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Figure 7.7. Schematic diagram of the combinatorial vectors. (A) The triple vectors contain a 
triple combination of anti-HIV-1 shRNAs and lhRNA expressed as independent transcriptional 
units. A total of four different triple vectors were obtained by using different promoters to express 
each RNAi trigger or by swapping the position of the RNAi trigger cassettes. Sequences and 
structure of the shRNAs and of the lhRNA have been previously described (Figure 7.1B). (B) The 
e-shRNA vectors encode a single hairpin encompassing 64 bp in the stem under the control of the 
U6, the 7SK or the H1 promoter. The e-shRNA gives rise to three distinct siRNAs targeting the 
CCR5, the tat/rev and the vif transcripts. The sequence and the predicted structure of the e-shRNA 
as well as the order of the siRNA-encoding sequences along the extent of the duplex are indicated. 
The guide strand sequences are marked in red, while G:U pairings are highlighted with an 
arrowhead (P: promoter). 
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7.6 Activity of the combinatorial vectors by means of the luciferase 
knockdown assay 
 
To determine whether the simultaneous expression of multiple RNAi triggers 
could affect the activity of the single siRNAs, the luciferase assay was performed. 
Initially, 293T cells were co-transfected with each combinatorial vector along 
with one single luciferase reporter plasmid. As regards the triple shRNA vectors, 
the reporter plasmids were the same used for testing the single shRNA vectors 
(i.e. psiCheck2-CCR5, psiCheck2-vif, psiCheck2-tat/rev) (7.2). By contrast, as far 
as the e-shRNA vectors is concerned, a new reporter plasmid was obtained to 
assess the silencing activity of the sitat/rev, whose target sequence is different 
from the ones of the lhtat/rev (psiCheck2-tat/rev*). 
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Figure 7.8. Knockdown of single luciferase reporter by the combinatorial vectors. Average 
normalized ratios of the renilla:firefly luciferase activity when cells were transfected with the 
indicated triple cassette (A) or e-shRNA (B) vector along with the psiCheck2-CCR5 (CCR5), 
psiCheck2-vif (vif), psiCheck2-tat/rev (tat/rev), or psiCheck2-tat/rev* (tat/rev*) reporter plasmid. 
As a control, cells were transfected with the corresponding reporter plasmid along with the 
vector(s) expressing the scrambled hairpin under the control of the U6, 7SK and/or H1 promoter, 
depending on the promoter driving the siRNAs. For convenience, only one control for each vector 
was plotted (C-). The average values from three independent experiments, with standard 
deviations, are given (*, p-value < 0.05; **, p-value < 0.01; ***, p-value < 0.001; t-test, relative to 
C-). 
 
As shown in Figure 7.8A, the shCCR5 and the lhtat/rev maintained a highly 
effective silencing activity when expressed in the context of a triple shRNA 
vector. On the other hand, the shvif mediated a less pronounced reporter gene 
knockdown, confirming the results obtained with the single shvif vectors. This 
finding was consistent regardless of either the employed promoter or the cassette 
position. Altogether, these data demonstrated that multiple siRNAs can be 
efficiently expressed as independent transcriptional units from a single construct, 
resulting in similar levels of inhibition per shRNA compared to the corresponding 
single shRNA vector.  
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On the contrary, as regards the e-shRNA, the silencing activity of the three RNAi 
effectors was comparable to that of the respective single shRNA vectors only 
when the extended molecule was expressed from the H1 promoter. Remarkably, 
this was true also for the sivif, despite it was positioned close to the hairpin loop. 
By contrast, either the U6 or the 7SK promoter mediated a highly inefficient 
effect (Figure 7.8B). 
Next, we moved further by co-transfecting reporters for CCR5, vif and tat/rev 
sequences all together along with each combinatorial vector. Indeed, this 
experimental setup allowed us to evaluate the overall silencing potential of the 
vectors, resembling the physiological condition of an HIV-1-infected cell 
expressing multiple siRNAs. 
 
 
Figure 7.9. Knockdown of multiple luciferase reporters by the combinatorial vectors. 
Average normalized ratios of the renilla:firefly luciferase activity when cells were transfected with 
the indicated triple cassette (A) or e-shRNA (B) vector along with the psiCheck2-CCR5, 
psiCheck2-vif and psiCheck2-tat/rev or psiCheck2-tat/rev* reporter plasmids (CCR5 + vif + 
tat/rev or CCR5 + vif + tat/rev*). As a control, cells were transfected with all the reporter plasmids 
along with the vector(s) expressing the scrambled hairpin under the control of the U6, 7SK and/or 
H1 promoter, depending on the promoter driving the siRNAs. For convenience, only one control 
for each vector was plotted (C-). The average values from three independent experiments, with 
standard deviations, are given (*, p-value < 0.05; **, p-value < 0.01; ***, p-value < 0.001; t-test, 
relative to C-). 
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The triple shRNA vectors displayed an overall reporter gene suppression higher 
than 70%, without major differences among them (Figure 7.9A). The same extent 
of luciferase knockdown was achieved by the H1-driven e-shRNA, while both the 
U6- and the 7SK-driven e-shRNA triggered a considerably lower effect (Figure 
7.9B). These results are consistent with data obtained by transfecting each 
reporter plasmid alone. Indeed, luciferase activity resulting from multiple reporter 
transfection was similar to the average activity calculated for the single reporter 
transfections, with respect to a given vector.  
Taken together, these data suggested that all the developed triple vectors as well 
as the H1-e-shRNA vector can produce multiple active siRNAs that are equally 
efficient in knocking down their respective targets, upon transfection of target 
cells. 
 
7.7 Analysis of combinatorial vector-related cytotoxicity 
 
The expression of antiviral genes may induce undesired effects, which could 
compromise host cell function. High levels of siRNA expression could decrease 
cell viability and might activate the interferon (IFN) response pathway, which can 
cause attenuated cell growth and apoptosis (Ringpis et al., 2012). To evaluate the 
biosafety of cells expressing multiple exogenous siRNAs, cell viability was 
assessed in cell cultures with and without siRNA expression. To this end, the 
MTT assay was undertaken in 293T cells, typically used for the production of 
lentiviral vector stocks, and in T lymphoblastoid Jurkat cells, a commonly used 
CD4+ T cell line permissive for HIV-1 infection. 293T cells underwent cell 
viability assay 48 h after transfection with either the combinatorial vectors or the 
scrambled counterpart, while Jurkat cells were assayed 72 h after vector 
transduction at an m.o.i. of 100 TU/cell. In all these experiments, the empty vector 
expressing no siRNAs was used as a control. 
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Vector EGFP+ cells (%) 
empty vector 91 ± 12 
U6scrambled 99 ± 1 
7SKscrambled 95 ± 6 
H1scrambled 99 ± 1 
U6shCCR5-H1lhtat/rev-H1shvif 58 ± 9 
U6shCCR5-H1lhtat/rev-7SKshvif 90 ± 14 
U6shCCR5- 7SKshvif- H1lhtat/rev 100 
7SKshCCR5-U6lhtat/rev-H1shvif 57 ± 3 
U6e-shRNA 67 ± 3 
7SKe-shRNA 67 ± 4 
H1e-shRNA 63 ± 7 
 
Figure 7.10. Absence of combinatorial vector-related cytotoxicity in cell lines. The pLL3.7 
empty vector, the multiple siRNA-expressing vectors and the scrambled vectors were employed 
either to transfect 293T cells (A) or to transduce Jurkat T cells (B). At 2 or 3 days, respectively, 
cell viability was measured by MTT assay. Cell viability of either transfected or transduced cells 
was calculated by measuring the absorbance at 620 nm and normalizing it to empty vector-
transfected or -transduced cells, respectively. The percentage of EGFP+ Jurkat cells 3 days after 
transduction is reported in Table 3. The means and standard deviations are derived from three 
independent experiments. 
 
Results in Figure 7.10 indicated that cell viability remained unaffected in both 
293T and Jurkat cells upon expression of multiple siRNAs. This was true despite 
the relatively high m.o.i. used for transduction of the latter cell line. FACS 
analysis revealed that transduction efficiency in Jurkat cells ranged between 57 
and 100%, based on the EGFP expression (Table 3). Importantly, these data 
allowed us to rule out that the lack of efficacy of the U6 and 7SKe-shRNA vectors 
was due to a decreased cell viability. 
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7.8 Effect of the combinatorial vectors on HIV-1 replication in cell 
cultures  
 
We next sought to evaluate the antiviral activity of the combinatorial vectors after 
de novo HIV-1 challenge. To this end, Jurkat cells were transduced with either 
each combinatorial vector (i.e. triple shRNA vectors and e-shRNA vectors) or 
control vector (i.e. U6-scrambled vector and empty vector), at an m.o.i. of 100 
TU/cell, in order to achieve high efficiency of transduction, without cytotoxic 
effects (7.7). Three days after transduction, EGFP+ cells typically ranged from 
67% to 97% (Table 4 and 5). Four days post-transduction, cells were challenged 
with the laboratory-adapted HXBc2 Vpr+ Vpu+ Nef+ strain of HIV-1. This virus 
encodes all the viral accessory proteins, resembling the scenario of an in vivo 
infection triggered by an HIV-1 primary isolate. Importantly, considering that the 
HXBc2 HIV-1 strain uses the CXCR4 co-receptor to enter target cells, in this 
experimental setup the contribution of the siCCR5 to the antiviral activity is not 
appreciable. Viral inhibition was assessed by measuring the RT activity in the cell 
culture supernatants at different time points. 
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Vector EGFP+ cells (%) 
empty vector 90 ± 9 
scrambled 96 ± 5 
U6shCCR5-H1lhtat/rev-H1shvif 70 ± 22 
U6shCCR5-H1lhtat/rev-7SKshvif 90 ± 10 
U6shCCR5-7SKshvif-H1lhtat/rev 97 ± 5 
7SKshCCR5-U6lhtat/rev-H1shvif 67 ± 17 
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Vector EGFP+ cells (%) 
empty vector 92 ± 9 
scrambled 97 ± 5 
U6e-shRNA 76 ± 12 
7SKe-shRNA 75 ± 11 
H1e-shRNA 76 ± 19 
 
 
 
Figure 7.11. Inhibition of CXCR4-tropic HIV-1 infection in Jurkat T cells transduced with 
the combinatorial vectors. Jurkat cells were transduced with the pLL3.7 empty vector, the 
U6scrambled vector (scrambled) and either the triple cassette vectors (A) or the e-shRNA vectors 
(B). The percentage of EGFP+ cells at 3 days post-transduction is reported in Tables 4 and 5, 
respectively. Untransduced (C+) and transduced cells were infected with the HXBc2 Vpr+ Vpu+ 
Nef+ strain of HIV-1 and the culture supernatants, harvested at various time points [3, 7 or 10 days 
post infection (d.p.i.)], were tested for RT activity, as indicated. Error bars denote the standard 
deviation from 3 independent experiments (C-: untransduced and uninfected cells) (*, p-value < 
0.05; **, p-value < 0.01; ***, p-value < 0.001; t-test, relative to C+ at the corresponding d.p.i.). 
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As shown in Figure 7.11A, HIV-1 replication was efficiently inhibited up to 7 
days post-infection in cells transduced with two out of the four triple shRNA 
vectors (i.e. U6shCCR5-H1lhtat/rev-7SKshvif and U6shCCR5-7SKshvif-
H1lhtat/rev), as compared either to untransduced infected cells (C+) or to 
scrambled- and empty vector-transduced cells. Furthermore, in the case of the 
U6shCCR5-7SKshvif-H1lhtat/rev vector, viral replication was nearly 
undetectable for as long as 10 days after infection, while, at the same time, the 
U6shCCR5-H1lhtat/rev-7SKshvif vector displayed a 10-fold decrease in viral 
replication. Strikingly, the U6shCCR5-H1lhtat/rev-H1shvif vector and the 
7SKshCCR5-U6lhtat/rev-H1shvif vector behaved similar to the scrambled 
control. These data are in sharp contrast with results obtained with the luciferase 
knockdown assay (7.6). One explanation to this finding could be that the 
U6shCCR5-H1lhtat/rev-H1shvif and the 7SKshCCR5-U6lhtat/rev-H1shvif 
vectors undergo genetic instability during the transduction process. Supporting 
this hypothesis, we noticed that their titer, expressed as TU/ml, was reduced of 
more than 4-fold as compared to the one of the effective vectors (Figure 7.12B), 
while the RT activity in the supernatant of producer cells displayed only slight 
differences (Figure 7.12A). Furthermore, when transducing target cells at the 
same m.o.i., transduction efficiency of the U6shCCR5-H1lhtat/rev-H1shvif and 
the 7SKshCCR5-U6lhtat/rev-H1shvif vectors was markedly lower than that of the 
U6shCCR5-H1lhtat/rev-7SKshvif and U6shCCR5-7SKshvif-H1lhtat/rev vectors 
(Figure 7.12C). 
On the other hand, results in Figure 7.11B demostrated that the H1-driven e-
shRNA provided a robust resistance to HIV-1 replication for as long as 10 days 
post-infection. By contrast, neither the U6-driven nor the 7SK-driven e-shRNA 
displayed antiviral activity. These data are consistent with the results obtained by 
means of the luciferase assay (7.6). 
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Figure 7.12. Differences in vector titer and transduction efficiency among the triple cassette 
vectors. (A) Equivalent amounts of supernatant from 293T cells, co-transfected with the 
packaging components along with each specified vector, were assayed for RT activity 2 days after 
transfection. (B) 293T cells were transduced with serial dilutions of the concentrated lentiviral 
stocks and, 72 h later, EGFP expression was assessed by flow cytometry, to determine vector 
titers. (C) Equivalent amounts of the indicated vectors were incubated with Jurkat T cells and, 72 h 
later, EGFP expression was analyzed by FACS, to determine transduction efficiency. The mean of 
three independent experiment is reported. The error bars represent the standard deviation (*, p-
value < 0.05; **, p-value < 0.01; t-test, relative to U6shCCR5-7SKshvif-H1lhtat/rev). 
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7.9 Inhibition of HIV-1 replication in human primary CD4+ T 
lymphocytes by means of the combinatorial vectors 
 
To confirm the results in a more physiologically relevant setting, we tested the 
ability of the combinatorial vectors to inhibit HIV-1 replication in primary CD4+ 
T cells, the major targets of HIV-1 infection in vivo. As a first step, CD4+ T 
lymphocytes were purified from the whole blood of healthy donors. To select the 
most appropriate purification protocol, T cell purity and yield obtained by using 
two different methods were compared. The first method involved the use of an 
antibody cocktail to separate unwanted cells from the CD4+ T cells, while the 
second one included a magnetic beads-based purification of CD4+ T cells. Details 
of the two protocols are described in the Materials and Methods section (6.2). The 
purity of the CD4+ T cell preparations and the presence of contamination with 
undesired cells (i.e. CD14+ monocytes, CD8+ T cells, CD19+ B cells) were 
assessed by flow cytometry, after staining with the appropriate antibodies. Given 
the results reported in Figure 7.13, the antibody cocktail-based technique was 
adopted thereafter to purify CD4+ T cells.  
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Figure 7.13. Purity of human primary CD4+ T lymphocytes prepared by different methods. 
CD4+ T cells were isolated by negative selection from buffy coats of healthy blood donors by 
using either an antibody cocktail (A) or magnetic beads (B) to separate unwanted cells from the 
CD4+ T cells. Purified cells were stained with antibodies to CD4, CD14 (monocyte/macrophage 
marker), CD8 (cytotoxic T lymphocyte marker) and CD19 (B lymphocyte marker). The expression 
of these surface markers was analyzed by flow cytometry. The results are exhibited as surface 
marker vs FSC dotplots with cell population in the live lymphocyte gate. The quadrant lines were 
defined by isotype control staining. 
 
After purification, T cells were PHA-activated for 48 h, to allow lentiviral 
transduction. We verified that either prolonged exposure to PHA or PMA 
stimulation in addition to PHA didn’t influence the activation status of T cells 
(data not shown). 
Next, activated T cells were transduced with the combinatorial vectors that have 
been proven to be effective in de novo infected Jurkat cells (i.e. U6shCCR5-
7SKshvif-H1lhtat/rev and H1e-shRNA) (7.8). Lymphocytes transduced with the 
empty vector served as control cells to measure uninhibited viral spread. Cells 
were spin-inoculated at an m.o.i. of 50 TU/cell in the presence of polybrene, 
achieving a percentage of EGFP+ cells typically up to 40% 72 h post-transduction 
(data not shown). Of note, although an m.o.i. of 50 was used for transduction with 
A B
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different vectors, actual transduction efficiency appeared to vary from donor to 
donor, with the empty vector always displaying the higher efficiency. Moreover, 
our results showed that the use of retronectin didn’t have a major impact on 
transduction efficiency, while in the absence of spin-inoculation, only a poor 
transduction efficiency was achieved (less than 10% on average, data not shown). 
Following transduction, T cells were cultured in the presence of human IL-2 and 
CCR5 cell surface expression was monitored at different time points by flow 
cytometry. As indicated in Figure 7.14, CCR5 expression on the surface of 
lymphocytes greatly varied depending on the donor. Unfortunately, we couldn’t 
detect major differences in CCR5 expression between combinatorial vector-
transduced cells and empty vector-transduced cells (data not shown). 
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Figure 7.14. Interdonor variability of CCR5 surface expression on human primary CD4+ T 
lymphocytes. Purified CD4+ T lymphocytes were stimulated with PHA for 48 h and further 
cultured in the presence of IL-2 for 4 days before FACS analysis for CCR5 expression on the cell 
surface. The FACS results are presented as CCR5 vs FSC dotplots with cell populations in the live 
lymphocyte gate (typically > 70%). The quadrant lines were defined by isotype control staining, as 
indicated. Results from three donors (1, 2 and 3) are shown. 
 
Taken together, these data prompted us to further investigate the antiviral activity 
of the combinatorial vectors in primary T cells upon HIV-1 challenge. To this 
end, CD4+ T lymphocytes were FACS sorted four days after transduction to 
obtain a pure EGFP+ population. The next day, cells were challenged with either 
the same X4-tropic HIV-1 strain previously described (HXBc2 Vpr+ Vpu+ Nef+) 
(7.8), or an R5-tropic HIV-1 strain (NL4-3-ADA). The latter virus is a laboratory-
adapted HIV-1 strain with intact accessory genes (vif, vpr, vpu, nef). Importantly, 
infection with the HIV-1 NL4-3-ADA strain allowed us to evaluate the 
contribution of the siCCR5 sequence to the antiviral activity, in addition to the 
effect of the siRNAs against the vif and the tat/rev transcripts. Infection was 
performed by using equivalent RT units (10000 cpm) of each virus and viral 
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inhibition was determined by measuring the RT activity in the cell culture 
supernatants at different time points. In parallel, to exclude vector-related 
cytotoxicity, CD4+ T cells underwent the MTT cell viability assay 4 days after 
transduction. 
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Figure 7.15. Inhibition of CXCR4- and CCR5-tropic HIV-1 infection in human primary 
CD4+ T lymphocytes transduced with the combinatorial vectors. PHA-stimulated purified 
CD4+ T lymphocytes were transduced with the pLL3.7 empty vector and the combinatorial 
vectors that displayed the highest antiviral activity upon Jurkat cell infection, as indicated. The 
transduced cells were cultured in IL-2-containing medium for 4 days before FACS sorting of 
EGFP+ cells. After additional 24 h, untransduced (C+) and FACS sorted EGFP+ T cells were 
challenged with either the HXBc2 Vpr+ Vpu+ Nef+ X4-tropic HIV-1 strain (A) or with the NL4-
3-ADA R5-tropic HIV-1 strain (B). Culture supernatants were collected on the days indicated [3, 7 
or 10 days post infection (d.p.i.)] and assayed for RT activity (C-: untransduced and uninfected 
cells). (C) Absence of combinatorial vector-related cytotoxicity in human primary CD4+ T 
lymphocytes. Cell viability of empty vector- and combinatorial vector-transduced T cells was 
measured by MTT assay 4 days after transduction. Cell viability was calculated by measuring the 
absorbance at 620 nm and normalizing it to untransduced cells. One representative experiment is 
shown (C-: untransduced and cells). 
 
Both the triple shRNA vector and the e-shRNA vector provided a robust 
inhibition of viral replication when challenged with either the X4- or the R5-HIV-
1 strain, relative to the controls [untransduced infected cells (C+) and empty 
vector-transduced cells] (Figure 7.15A-B). Further, viral inhibition was sustained 
for as long as 10 days after infection. Of note, the siRNAs expressed from the 
triple vector mediated the most potent antiviral effect in primary cells. 
Importantly, lymphocyte viability remained unaffected despite both the 
transduction process and the multiple exogenous siRNAs expression (Figure 
7.15C). 
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Figure 7.16. ISs distribution of the vectors in human primary CD4+ T lymphocytes. (A) 
Visual representation of an ISs cluster region on chromosome 17 (UCSC genome browser). 
Location of the cluster is indicated by a red rectangle on the chromosome (top). Zoom-in of the 
corresponding region (bottom). The base position feature (scale bar and nucleotide number) 
identifies the genomic coordinates of the displayed region. The RefSeq genes track shows known 
human protein-coding transcripts taken from the NCBI RNA reference sequences collection. (B) 
Distribution of ISs with respect to either RefSeq genes (left panel) or exons/introns (right panel). 
(C) Functional classification of genes targeted by ISs. The figure shows those function categories 
significantly over-represented among the target genes of vector integrations in CD4+ T cells 
(DAVID 6.7 software). A p-value < 0.05 was considered as statistically significant (1.3 in log 
scale, vertical line), (**, p-value < 0.01; ***, p-value < 0.001), (n) represents the total number of 
genes eligible for the analysis. 
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Despite the limited amount of annotated ISs, vectors showed a marked preference 
for intragenic insertion, and in particular for introns, since only 3 out of 79 
intragenic ISs targeted exons (4%) (Figure 7.16B). Importantly, no major 
differences were detected between the empty vector and the combinatorial 
vectors, indicating that increased vector size, presence of multiple promoters or 
transgene sequences didn’t alter the integration profile. 
The Gene Ontology (GO) functional classification of the ISs target genes showed 
significant enrichment of specific categories. In particular, genes targeted by the 
empty vector integration are involved in protein modification, transcriptional 
regulation and RNA processing (p-value < 0.05) (Figure 7.16C, upper panel). The 
same or very similar functional categories (i.e. protein modification and regulation 
of RNA processing) were significantly enriched also in the set of genes hosting 
the triple vector integrations (p-value < 0.05) (Figure 7.16C, middle panel). 
Notably, the enrichment of related functional categories in the collection of genes 
targeted by the empty vector and the triple cassette vector was determined by 
different genes. Indeed, we never detected the same gene simultaneously hit by 
more than one vector (data not shown). On the contrary, the categories 
significantly over-represented in the e-shRNA vector dataset included phosphorus 
and phosphate metabolic processes, axon and neurons ensheathment and 
phosphorylation (p-value < 0.05) (Figure 7.16C, bottom panel). 
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8. DISCUSSION 
 
Despite major advances in antiretroviral therapy, HIV-1 infection remains an 
epidemic cause of morbidity and mortality. Effective antiretroviral therapy often 
involves costly, multi-drug regimens that are not well tolerated by a significant 
percentage of patients, and even successful adherence to the therapy does not 
eradicate the virus, since a rapid rebound in HIV-1 levels can occur if therapy is 
discontinued.  
An alternative, or complementary, approach to control HIV-1 replication is 
engineering the body’s immune cells to be resistant to infection (Baltimore, 
1988). In this context, over the past years, several anti-HIV-1 gene therapy 
approaches have been tested in hematopoietic stem cells (HSCs). These cells 
represent an attractive target, since they are the precursors of all the cells involved 
in HIV-1 pathogenesis (i.e. CD4+ T lymphocytes, macrophages, dendritic cells 
and microglia), and, thus, their genetic modification could protect the entire 
spectrum of susceptible cells. As HSCs proliferate extensively once they begin to 
contribute to blood cell production, they may function for years as an enduring 
source of HIV-1-resistant cells to replenish central and mucosal lymphoid organs. 
Thus, differently from lifelong drug therapy, a successful gene therapy protocol 
should be effective after a single treatment.  
Recently, the development of HSC-based gene therapy approaches for HIV-1 
infection received renewed attention thanks to the case of the Berlin patient. This 
HIV-1 infected individual was transplanted with HSCs from a donor homozygous 
for a deletion in the CCR5 gene (CCR5∆32), as a treatment for leukemia. The 
CCR5∆32 mutation prevents the CCR5 from appearing on the cell surface, 
without apparent adverse phenotypic effects. Since the majority of naturally 
occurring strains of HIV-1 uses CCR5 as a co-receptor for primary infection, 
individuals homozygous for the CCR5∆32 are resistant to HIV-1 infection 
(Samson et al., 1996). Notably, the Berlin patient is currently free from HIV-1 
replication, while also having discontinued antiretroviral drug therapy (Hütter et 
al., 2009; Hütter and Ganepola 2011a; Burke et al., 2013). This proof-of-principle 
study demonstrated that HIV-1-resistant stem cells are capable of repopulating the 
immune system, providing a functional cure for HIV-1 infected patients.  
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The safety of numerous anti-HIV-1 genes has been demonstrated in previous 
HIV-1 stem cell gene therapy clinical trials, including both RNA- and protein-
based inhibitors. To date, preclinical studies indicated that RNAi is the most 
potent RNA-based inhibitory mechanism available for therapeutic application, 
especially when induced via stable shRNA expression (Rossi et al., 2007; Liu et 
al., 2009). However, given the high rates of HIV-1 production in infected 
individuals and the ability of HIV-1 to generate escape variants, effective 
therapeutic application of RNAi for HIV-1 disease should involve the 
combination of multiple “genetic immunization” reagents directed against the 
virus (An et al., 2007). Therefore, similar to combination approaches with 
antiviral drugs, multiple anti-HIV-1 genes inserted into a single gene therapy 
vector may offer stronger protection from viral infection and will have a greater 
chance of preventing resistance (Li et al., 2005; Sano et al., 2008; ter Brake et al., 
2008; Saayman et al., 2008; Liu et al., 2009; Walker et al., 2012; Centlivre et al., 
2013). Combinatorial RNAi (co-RNAi) has been achieved by means of a number 
of different strategies, among which multiple promoter-shRNA cassettes and 
extended shRNAs (e-shRNAs) are the most extensively exploited. Although all of 
these approaches can result in efficient gene suppression, only few studies directly 
compare the efficacy of different co-RNAi platforms designed against the same 
targets, as well as the impact of promoter choice on the expression of a given 
RNAi effector. 
In the present work, we developed lentiviral vectors expressing multiple anti-
HIV-1 siRNAs, both as independent transcriptional units, and as an e-shRNA 
under the control of a single promoter. Our aims were to evaluate the impact of 
different promoters on siRNA silencing activity, to compare the antiviral efficacy 
of multiple co-RNAi platforms and to optimize vector design. The final goal of 
the research project is to use the most effective and safe vector(s) for transducing 
HSCs harvested from AIDS-related lymphoma (ARL) patients, that offer a unique 
opportunity to evaluate gene therapy strategies in an ethically acceptable clinical 
setting, as they often undergo autologous HSCs transplantation.  
To achieve reliable HIV-1 inhibition, we sought to block multiple stages of the 
viral life cycle by targeting a combination of cellular and viral genes, namely the 
CCR5, tat, rev and vif genes. After having searched for active RNAi triggers in 
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literature, we selected shRNAs, generating one single siRNA, against either the 
CCR5 (shCCR5) (Liang et al., 2010) or the vif transcript (shvif) (Lee et al., 2005), 
and a long hairpin RNA (lhRNA), simultaneously giving rise to two different 
siRNAs against the tat and rev overlapping first exons (lhtat/rev) (Sano et al., 
2008). All these molecules proved to be highly effective against HIV-1 
replication, since they target essential functions in the viral life cycle, including 
entry into target cells (shCCR5) (Liang et al., 2010), gene expression (lhtat/rev) 
(Sano et al., 2008) and infectivity of the newly produced particles (shvif) (Lee et 
al., 2005). Moreover, the selected hairpins provide the following advantages: 
firstly, targeting of cellular co-factors such as CCR5 represents a valuable anti-
escape approach, considering that the chance of resistance mutations in host 
transcripts is negligible compared to HIV-1 sequences; secondly, both the shvif 
and the lhtat/rev target conserved viral sequences, to prevent the selection of HIV-
1 escape variants (Lee et al., 2005; Sano et al., 2008). In particular, the lhtat/rev, 
which produces two distinct siRNAs, is superior over a single shRNA in terms of 
longevity of viral inhibition.  
In the first part of the work, we addressed the influence of the promoter used to 
express each RNAi trigger on its silencing activity. To this end, vectors 
expressing the shCCR5, the shvif or the lhtat/rev as a single transcriptional unit 
under the control of different human polymerase III promoters were constructed. 
Selected promoters included U6 and H1, which are the most widely exploited 
shRNA promoters, as well as the less frequently used 7SK promoter. These 
promoters are compact, active in many tissues and possess well known 
transcription start sites and termination signals. When assayed in the context of 
the luciferase knockdown assay, in which the RNAi target sequence is fused with 
the luciferase reporter gene, the U6 and the H1 promoters mediated an overall 
suppressive activity higher than that observed in the case of 7SK, irrespective of 
the RNAi effector. Furthermore, in our experimental settings, while the H1 and 
the U6 promoters displayed comparable activity in downregulating the CCR5 
target sequence, H1 was superior to U6 in the case of the vif and tat/rev 
sequences. Literature data are controversial and only few studies directly compare 
the activity of different Pol III promoters. Results obtained by Mäkinen et al. 
indicated that the U6 promoter is more efficient than H1 in GFP silencing in vitro 
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and in vivo, leading to stable GFP knockdown in mouse brain for at least 9 months 
(Mäkinen et al., 2006). By contrast, ter Brake and colleagues observed similar 
reporter gene knockdown when comparing the activity of the U6, the 7SK and the 
H1 promoters, driving the expression of shRNAs against the HIV-1 pol, gag and 
tat/rev transcripts (ter Brake et al., 2008). Overall, our results suggested that the 
U6 and the H1 promoters are stronger than 7SK, but their activity may be 
influenced by the sequence, the structure and/or the length of the downstream 
RNAi trigger. 
Consistent with these data, we demonstrated that CCR5 is downregulated by the 
shCCR5 both in the Cf2Th CD4+/CCR5+ canine thymocyte cell line and, more 
importantly, in human primary macrophages, with the U6 and the H1 promoters 
performing typically better than 7SK.  
It is well known that CCR5 receptor density determines the susceptibility against 
HIV-1 transmission (Samson et al., 1996; Michael et al., 1997; Reynes et al., 
2001), and it has been shown that a linear decrease in CCR5 expression results in 
a logarithmic decrease in HIV-1 infection in vitro (Butticaz et al., 2003). Indeed, 
CCR5∆32 heterozygotes, whose CCR5 is reduced to 20-30% of wild-type levels, 
have a diminished susceptibility and progression of HIV-1 disease (Huang et al., 
1996; Meyer et al., 1997; Quillent et al., 1998). Given these considerations, the 3-
fold CCR5 downregulation on primary macrophages we obtained in the presence 
of the shCCR5, as compared to untransduced cells, could have a marked clinical 
effect. Our results are consistent with those obtained by Liang and colleagues, that 
achieved an approximately 3-fold reduction of CCR5 expression in macrophages 
derived from human fetal liver (FL) CD34+ cells transduced with the shCCR5 
molecule (Liang et al., 2010). In that context, the observed CCR5 downregulation 
was sufficient to strongly inhibit viral replication after challenge with an R5-
tropic HIV-1 strain (Liang et al., 2010). 
Previous studies performed by David Baltimore and collaborators identified an 
alternative shRNA against the CCR5, determining a 10-fold reduction in CCR5 
expression on CD8+-depleted peripheral blood lymphocytes (Qin et al., 2003). 
However, the expression of this shRNA from the U6 promoter resulted in 
cytotoxicity in primary cells, while the expression from other promoters highly 
95 
 
impaired shRNA potency, thus this antiviral molecule was no longer employed 
(An et al., 2006, 2007). 
Next, we tried to dissect the biological activity of the lhtat/rev by examining the 
effect of targeting either the HIV-1 Tat or Rev protein. Our results indicated that 
the lhtat/rev-mediated downregulation of either one of these proteins caused only 
a rather modest inhibition of viral gene expression in transfected or infected cells. 
On the one hand, a more pronounced inhibitory effect might have been 
accomplished by sorting of the lhRNA-transduced cells, as recently reported 
(Kalomoiris et al., 2012). On the other hand, in our experimental conditions, only 
a tiny amount of Rev was required to express the gag gene, making it challenging 
to observe the effect of Rev dowregulation.  
Compared with the shCCR5 and the lhtat/rev, the shvif displayed an overall less 
potent suppressive activity against its target in the luciferase assay. However, this 
siRNA proved to be broadly potent in previous studies, conferring protection 
against HIV-1 strains from multiple clades, by virtue of the high degree of target 
sequence conservation (Lee et al., 2005). In addition, it is noteworthy that even 
small alteration in the expression or function of critical genes can influence the 
efficacy of HIV-1 transmission, viral load and collapse of the immune system 
(Ioannidis et al., 2001; Alexander et al., 2002; Fellay et al., 2007; Rangel et al., 
2009; Hütter et al., 2013).  
Starting from these results, we developed anti-HIV-1 combinatorial vectors 
simultaneously expressing the above described siRNAs, according to different 
strategies. In general, the insertion of independent transcriptional units within a 
single vector offered the most reliable and predictable gene knockdown (Lambeth 
et al., 2010; Centlivre et al., 2013). Thus, we designed different vectors 
containing three independent transcriptional units, encoding the shCCR5, the 
shvif and the lhtat/rev, positioned in different orders with respect to each other 
within the vector framework. In some context, the same promoter was employed 
to drive the expression of multiple RNAi triggers, while in other context distinct 
promoters were adopted (triple vectors, i.e. U6shCCR5-H1lhtat/rev-H1shvif; 
U6shCCR5-H1lhtat/rev-7SKshvif; U6shCCR5-7SKshvif-H1lhtat/rev; 
7SKshCCR5-U6lhtat/rev-H1shvif).  
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Considering that the use of multiple highly active RNA Pol III promoters can 
potentially flood the cell with shRNAs and abrogate the natural microRNA 
biogenesis pathway (Yi et al., 2005; Grimm et al., 2006; Boudreau et al., 2008), 
we further adopted an e-shRNA molecule, as an alternative combinatorial 
approach. The e-shRNA simultaneously expresses the three siRNAs, targeting the 
CCR5, the vif and the tat/rev transcripts, under the control of a single promoter (e-
shRNA vectors, i.e. U6e-shRNA; 7SKe-shRNA; H1e-shRNA).  
Initial luciferase assays performed with the triple vectors indicated that, upon 
transfection of target cells, all the developed constructs were effective, as the 
individual shRNA activity was comparable for single and multiple shRNA 
vectors. However, a strikingly different pattern emerged when transduced 
lymphoblastoid Jurkat T cells were infected with a CXCR4-tropic strain of HIV-1. 
Indeed, in this latter case, only the U6shCCR5-H1lhtat/rev-7SKshvif and the 
U6shCCR5-7SKshvif-H1lhtat/rev vectors efficiently controlled HIV-1 replication 
up to 10 days post-infection, and the U6shCCR5-7SKshvif-H1lhtat/rev vector 
almost completely abolished viral infection, causing a 35-fold reduction of the 
total viral load. On the contrary, neither the U6shCCR5-H1lhtat/rev-H1shvif or 
the 7SKshCCR5-U6lhtat/rev-H1shvif conferred protection against HIV-1. 
Interestingly, these latter vectors displayed lower titer and transduction efficiency 
than the U6shCCR5-H1lhtat/rev-7SKshvif and the U6shCCR5-7SKshvif-
H1lhtat/rev vectors, as measured by EGFP expression. One possible explanation 
for these results might be the occurrence of recombination events, resulting in 
deletion of one or more therapeutic cassettes. Supporting this hypothesis, previous 
studies have shown that the presence of repeated promoters causes frequent 
recombination within the lentiviral vector genome during the transduction process 
(ter Brake et al., 2008), with a correlation between the length of the repeated 
sequence and the frequency of deletions (An et al., 2001). The presence of 
repeated promoters may have a detrimental effect for the U6shCCR5-H1lhtat/rev-
H1shvif vector, since it harbours two copies of H1. However, this is not likely to 
be a general rule, considering that a lentiviral vector expressing multiple anti-
HIV-1 genes under the control of repeated Pol III promoters not only conferred 
strong resistance to HIV-1 infection (Li et al., 2005), but it is also currently tested 
in phase I clinical trial (DiGiusto et al., 2010). Thus, other key factors might 
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contribute to determine vector stability upon transduction of target cells, 
potentially influencing the reverse transcriptase activity. Among these, the local 
structure assumed by the vector genome, influenced by either the specific 
combination or the relative position of the shRNA cassettes, might play an 
important role.  
By contrast, in the case of the e-shRNA vectors, the results obtained with both the 
luciferase assay and the viral challenge of transduced Jurkat cells clearly indicated 
that, among those tested, H1 was the only effective promoter in driving the 
expression of multiple siRNAs. Probably, in this context, promoter sequence 
directly impacts upon efficient processing and production of mature siRNAs, 
possibly through changes in their thermodynamic properties. To our knowledge, 
this is the first study directly comparing the impact of different promoters on e-
shRNA expression.  
The H1-driven e-shRNA determined a 20-fold reduction of the total viral load 10 
days post-HIV-1 infection in Jurkat cells. Despite such a robust inhibition of viral 
replication, these data indicated that the e-shRNA vector was slightly less efficient 
than the most potent triple vector (i.e. U6shCCR5-7SKshvif-H1lhtat/rev). 
Eventually, some viral breakthrough occurred for both the triple and the e-shRNA 
vectors over the 4-weeks time course of HIV-1 replication in Jurkat cells (data not 
shown). This observation could reflect several mechanisms, such as sub-optimal 
inhibitory RNAi regimen, variability of inhibition over time and generation of 
escape or pseudo-escape viruses, that appear when a high virus input is tested 
(Qin et al., 2003; Knoepfel et al., 2012). In addition, it is important to remember 
that, on the one hand, the challenge virus was a CXCR4-tropic strain of HIV-1, 
thus only siRNAs targeting vif and tat/rev, but not CCR5, contributed to the 
observed antiviral activity. On the other hand, the EGFP+ cells were not sorted 
upon transduction, thus they are bathed continuously in virus produced by the 
unprotected cells.  
The antiviral activity of the most promising triple and e-shRNA vectors (i.e. 
U6shCCR5-7SKshvif-H1lhtat/rev and H1e-shRNA) was further confirmed and 
extended in human primary CD4+ T lymphocytes, which are the major targets of 
HIV-1 infection in vivo. Consistent with previous data, the triple vector showed 
on average a 2-fold higher HIV-1 inhibition than the e-shRNA vector over the 10-
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days time course of infection. In this context, we couldn’t observe vector-
mediated CCR5 downregulation, a finding most likely due to the low level of its 
expression on the surface of T cells. 
Given that HSC transplantation is for a lifetime, the challenge is to identify 
shRNAs with sufficient potency to downregulate the desired genes over sustained 
lengths of time, but without toxicity to the cells bearing them. It has been 
previously shown that RNAi can cause toxic effects and trigger the induction of 
interferon response, leading to the loss of the transduced cells (Bridge et al., 2003; 
Sledz et al., 2003). In this regard, we included G:U mismatches in the passenger 
strand of the lhRNA and the e-shRNA, as they have been shown to prevent the 
activation of IFN-inducible genes, evading recognition by dsRNA-binding 
proteins in the cytoplasm (Sano et al., 2008). In addition, our results ruled out a 
decrease in cell viability due to multiple siRNA expression, both in cell lines and 
in human primary T cells.  
Apart from interferon induction, vectors integration profile represents an 
important safety issue, with significant consequences on their potential 
genotoxicity. Indeed, in the seminal clinical trials of HSC gene therapy for severe 
combined immunodeficiency (SCID) carried out by Cavazzana and colleagues, 
the clinical benefit of gene transfer was tempered by the occurrence of vector-
related leukemia in some patients. In all these patients the therapeutic 
gammaretroviral vector integrated near proto-oncogenes and altered their 
expression, thereby promoting clonal T cell proliferation (Hacein-Bey-Abina et 
al., 2003a,b, 2008). Several studies have probed the integration target site 
selection by gammaretroviruses, indicating that they preferentially integrate near 
transcriptional start sites and other transcriptional regulatory regions, such as CpG 
islands and DNAse I hypersensitive sites.  This increases the risk to alter 
expression of nearby cellular genes, including proto-oncogenes and genes with 
regulatory functions (Wu et al., 2003; Bushman et al., 2005; Felice et al., 2009 
Montini et al., 2009; Deichmann et al., 2011; Sharma et al., 2013). By contrast, 
lentiviral vectors integrate throughout the body of active genes, without showing a 
bias for promoter-proximal regions (De Palma et al., 2005; Montini et al., 2006; 
Zhou et al., 2010; Cattoglio C et al., 2010; Cartier et al., 2012). These data 
suggested that lentiviral vectors might have a reduced risk to alter transcriptional 
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regulation, even if they could still impact on the cellular transcriptome by 
inducing the formation of aberrantly spliced mRNAs (Cesana et al., 2012; Moiani 
et al., 2012). Consistent with literature data, our results, performed on a limited 
number of annotated ISs, indicated a vector integration preference for intragenic 
regions, especially for introns, in human primary T cells. Importantly, in this 
context, we didn’t detect major differences between the vectors expressing 
multiple anti-HIV-1 siRNAs and the control vector. In addition, functional 
clustering analysis indicated that the triple and the control vectors share a 
common tendency to integrate within genes involved in protein modification and 
regulation of RNA metabolism. On the other hand, the e-shRNA vector 
preferentially targeted genes involved in phosphorous/phosphate metabolism and 
in neuron physiology. If supported by a deeper investigation, this latter evidence 
could have relevant implications for a possible use of the e-shRNA vector in gene 
therapy approaches for HIV-1 infection. Indeed, vector insertions within genes 
unrelated to both CD4+ T cell biology and transcriptional regulation might 
decrease the risk of adverse events. We are currently extending the collection of 
annotated ISs by next-generation sequencing of vector-genome junctions, in order 
to perform a detailed genome-wide analysis of vectors integration profile. 
In conclusion, we described here new potent combinatorial approaches which may 
contribute to the development of an RNAi-based gene therapy strategy against 
HIV-1 infection. To our knowledge, this is the first time that multiple RNAi 
triggers targeting both viral and cellular genes are combined within a single 
vector. To date, anti HIV-1 gene therapy trials have mainly employed dominant 
negative proteins, ribozymes, antisense RNAs and decoys (reviewed in Hoxie and 
June, 2012). In 2008, the first shRNA against tat/rev was used in combination 
with a TAR decoy and a CCR5-ribozyme as an RNA-based HIV-1 gene therapy 
approach (DiGiusto et al., 2010). This initial clinical result provided 
encouragement for the use of RNAi-based agents to fight HIV-1 infection and, 
currently, the first lentiviral vector expressing a triple combination of anti-HIV-1 
shRNAs against the pol and tat/rev transcripts is approaching clinical testing 
(Knoepfel et al., 2012).  
In addition, our study highlighted some important strengths and pitfalls of 
different platforms used for multiple siRNAs delivery, providing valuable insights 
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for the design and application of reliable combinatorial RNAi to counteract HIV-1 
replication.  
Future studies will address vector efficacy and safety in HSCs, which represent 
the main targets of our anti-HIV gene therapy approach, as well as in humanized 
mouse models. As a result of this work, hopefully we should be able to build up a 
clinical protocol to genetically modify HSCs harvested from ARL patients. In this 
context, it is noteworthy to consider that, to fully exploit the therapeutic potential 
of the vectors, the gene therapy approach will be restricted to individuals with no 
detectable CXCR4-tropic virus. 
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